EP1827486A2 - Nouvelles entites biologiques et utilisation ciblee de celles-ci - Google Patents

Nouvelles entites biologiques et utilisation ciblee de celles-ci

Info

Publication number
EP1827486A2
EP1827486A2 EP05823713A EP05823713A EP1827486A2 EP 1827486 A2 EP1827486 A2 EP 1827486A2 EP 05823713 A EP05823713 A EP 05823713A EP 05823713 A EP05823713 A EP 05823713A EP 1827486 A2 EP1827486 A2 EP 1827486A2
Authority
EP
European Patent Office
Prior art keywords
positions
protease
peptide bonds
protein
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05823713A
Other languages
German (de)
English (en)
Inventor
Ulrich c/o Direvo Biotech Ag HAUPTS
Andre c/o DIREVO Biotech AG Koltermann
Andreas c/o Direvo Biotech Ag SCHEIDIG
Ulrich c/o DIREVO Biotech AG Kettling
Wayne Michael c/o Direvo Biotech Ag COCO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Voetsmeier Christian
Direvo Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voetsmeier Christian, Direvo Biotech AG filed Critical Voetsmeier Christian
Priority to EP05823713A priority Critical patent/EP1827486A2/fr
Publication of EP1827486A2 publication Critical patent/EP1827486A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides methods for the treatment of a disease by applying a m edicament com prising a protease with a defined specificity is capable to hydrolyze specific peptide bonds within a target substrate related to such disease.
  • the proteases with such a defined specificity can further be used for related therapeutic or diagnostic purposes.
  • NBEs New Biologic Entities
  • the NBEs disclosed in the present invention are engineered enzymes with novel substrate specificities or fusion proteins of such engineered enzymes with other functional com ponents.
  • Specificity is an essential element of enzym e function.
  • a cell consists of thousands of different, highly reactive catalysts. Yet the cell is able to maintain a coordinated metabolism and a highly organized three-dimensional structure. This is due in part to the specificity of enzym es, i.e. the selective conversion of their respective substrates.
  • Specificity is a qualitative and a quantitative property: the specificity of a particular enzyme can vary widely, ranging from j ust one particular type of target molecules to all molecular types with certain chem ical substructures. I n nature, the specificity of an organism 's enzymes has been evolved to the particular needs of the organism .
  • antibodies contain com plementarity determ ining regions (CDRs) which interact with the antigen in a highly specific manner and allow discrim ination even between very sim ilar epitopes.
  • CDRs com plementarity determ ining regions
  • the light as well as the heavy chain of the antibody each contribute three CDRs to the binding domain.
  • Nature uses recombination of various gene segments combined with further m utagenesis in the generation of CDRs.
  • the sequences of the six CDR loops are highly variable in com position and length and this forms the basis for the diversity of binding specificities in antibodies.
  • a sim ilar principle for the generat ion of a diversity of catalytic specificities is not known from nature.
  • Catalysis i.e. the increase of the rate of a specific chem ical reaction, is besides binding the most im portant protein function.
  • Catalytic proteins i.e. enzymes, are classified according to the chem ical reaction they catalyze.
  • Transferases are enzymes transferring a group, for exam ple, the methyl group or a glycosyl group, from one com pound (generally regarded as donor) to another com pound (generally regarded as acceptor) .
  • glycosyltransferases ( EC 2.4) transfer glycosyl residues from a donor to an acceptor molecule.
  • Some of the glycosyltransferases also catalyze hydrolysis, which can be regarded as transfer of a glycosyl group from the donor to water.
  • the subclass is further subdivided into hexosyltransferases ( EC 2.4.1 ) , pentosyltransferases ( EC 2.4.2) and those transferring other glycosyl groups ( EC 2.4.99 , Nomenclature Com m ittee of the I nternational Union of Biochem istry and Molecular Biology ( NC- I UBMB)) .
  • Oxidoreductases catalyze oxido- reductions.
  • the substrate that is oxidized is regarded as hydrogen or electron donor.
  • Oxidoreductases are classified as dehydrogenases, oxidases, mono - and dioxygenases.
  • Dehydrogenases transfer hydrogen from a hydrogen donor to a hydrogen acceptor molecule.
  • Oxidases react with molecular oxygen as hydrogen acceptor and produce oxidized products as well as either hydrogen peroxide or water.
  • Monooxygenases transfer one oxygen atom from molecular oxygen to the substrate and one is reduced to water. I n contrast, dioxygenases catalyze the insert of both oxygen atoms from molecular oxygen into the substrate.
  • Lyases calalyze elim ination reactions and thereby generate double bonds or, in the reverse direction, catalyze the additions at double bonds, l somerases catalyze intramolecular rearrangements.
  • Ligases catalyze the formation of chem ical bonds at the expense of ATP consum ption .
  • hydrolases are enzym es that catalyze the hydrolysis of chem ical bonds like C-O or C- N.
  • the E.C. classification for these enzymes generally classifies them by the nature of the bond hydrolysed and by the nature of the substrate.
  • Hydrolases such as lipases and proteases play an im portant role in nature as well in technical applications of biocatalysts.
  • Proteases hydrolyse a peptide bond within the context of an oligo- or polypeptide.
  • proteases are grouped into aspartic, serin, cysteine, metallo - and threonine proteases ( Handbook of proteolytic enzymes.
  • the residues on the island C-terminal side of the scissile bond are usually called P 1 , P 2 , P 3 etc and P 1 ', P 2 ', P 3 ' and the binding pockets com plementary to the substrate S 1 , S 2 , S 3 and S 1 ', S 2 ', S 3 ', respectively (nomenclature according to Schlechter & Berger, Biochem . Biophys. Res. Com m un. 27 ( 1 967) 157-162) .
  • the selectivity of proteases can vary widely from being virtually nonselective - e.g. the Subtilisins - over a strict preference at the P position - e.g.
  • proteases i.e. their ability to recognize and hydrolyze preferentially certain peptide substrates
  • Qualitative specificity refers to the kind of am ino acid residues that are accepted by a protease at certain positions of the peptide substrate.
  • trypsin and t- PA are related with respect to their qualitative specificity, since both of them require at the P 1 position an arginine or a sim ilar residue.
  • Enzyme additives in detergents have come to constitute nearly a third of the whole industrial enzyme market.
  • Detergent enzymes include proteinases for removing organic stains, lipases for rem oving greasy stains, amylases for removing residues of starchy foods and cellulases for restoring of sm ooth surface of the fiber.
  • the best- known detergent enzyme is probably the nonspecific proteinase subtilisin, isolated from various Bacillus species.
  • Starch enzym es, such as amylases occupy the majority of those used in food processing. While starch enzymes include products that are im portant for textile desizing, alcohol fermentation, paper and pulp processing, and laundry detergent additives, the largest application is for the production of high fructose corn syrup. The production of corn syrup from starch by means of industrial enzymes was a successful alternative to acid hydrolysis.
  • enzymes are used for an increasing range of applications in food. Enzymes in food can im prove texture, appearance and nutritional value or may generate desirable flavours and arom as.
  • Currently used food enzymes in bakery are amylase, amyloglycosidases, pentosanases for breakdown of pentosan and reduced gluten production or glucose oxidases to increase the stability of dough .
  • Com m on enzymes for dairy are rennet (protease) as coagulant in cheese production, lactase for hydrolysis of lactose, protease for hydrolysis of whey proteins or catalase for the removel of hydrogen peroxides.
  • Enzymes used in brewing process are the above named amylases, but also cellulases or proteases to clarify the beer from suspended proteins. I n wines and fruit juices, cloudiness is more com menly caused by starch and pectins so that amylases and pectinases increase yield and clarification. Papain and other proteinases are used for meat tenderizing.
  • Enzymes have also been developed to aid animals in the digestion of feed. I n the western hem isphere, corn is a major source of food for cattle, swine, and poultry. I n order to im prove the bioavailability of phosphate from corn, phytase is com monly added (Wyss, M. et al., Biochem ical characterization of fungal phytases (myo- inositol hexakisphosphate phosphohydrolases) ; Catalytic properties. Applied & Environmental Microbiology 65, 367-373 ( 1 999)) .
  • Xylanases cause two im portant actions: reduction of viscosity of the intestinal contents by hydrolyzing the gel- like high molecular weight arabinoxylans in feed ( Murphy, T et al., Effect of range of new xylanases on in vitro viscosity and on performance of broiler diets. British Pultry Science 44, S16-S1 8 (2003)) and break down of polymers in cell wallswhich im prove the bioavailability of protein and starch.
  • Biotech research and development laboratories routinely use special enzymes in small quantities along with many other reagents. These enzymes create a significant market for various enzymes. Enzymes like alkaline phosphatase, horseradish peroxidase and luciferase are only some exam ples. Thermostable DNA polymerases like Taq polymerase or restriction endonucleases revolutionized laboratory work.
  • Therapeutic enzymes are a particular class of drugs, categorized by the FDA as biologicals, with a lot of advantages com pared to other, especially non-biological pharmaceuticals.
  • Exam ples for successful therapeutic enzymes are human clotting factors like factor VI I I and factor IX for human treatment. I n addition, digestive enzymes are used for various deficiencies in human digestive processes.
  • Other exam ples are t- PA and streptokinase for the treatment of cardiovascular disease, beta-glucocerebrosidase for the treatment of Type I Gaucher disease, L- asparaginase for the the treatment of acute lym phoblastic leukem ia and DNAse for the treatment of cystic fibrosis.
  • Proteases represent an im portant class of therapeutic agents (Drugs of today, 33, 641 -648 ( 1997)) .
  • the therapeutic protease is usually a substitute for insufficient acitivity of the body's own proteases.
  • factor VI I can be adm inistered in certain cases of coagulation deficiencies of bleeders or during surgery ( Heuer L. ; Blumenberg D. (2002) Anaest hesist 51 : 388) .
  • Tissue-type plasm inogen activator (t- PA) is applied in acute cardiac infarction, initializing the dissolution of fibrin clots through specific cleavage and activation of plasm inogen (Verstraete, M. et al. ( 1995) Drugs, 50, 29-41 ) . So far a protease with taylor-made specificity is generated to provide a therapeutic agent that specifically activates or inactivates a disease related target protein.
  • TNFs tumor necrosis factors
  • cytokines cytokines
  • TNFs tumor necrosis factors
  • the most im portant TNFs are TNF- alpha and TNF-beta.
  • TNF-alpha is produced by macrophages, monocytes and other cells.
  • TNF-alpha is an inflam mation mediator.
  • TNF-alpha inhibitors like monoclonal antibodies as possible therapeutics for different therapeutic indications like Rheumatoid Arthritis, Crohn ' s disease or Psoriasis ( Ham ilton et al. (2000) Expert Opin Pharmacother, 1 (5) : 1041 -1 052) .
  • TNF-alpha inhibitors like monoclonal antibodies
  • Psoriasis Ham ilton et al. (2000) Expert Opin Pharmacother, 1 (5) : 1041 -1 052
  • One of the m ajor disadvantages of m onoclonal antibodies are their high costs, so that new biological alternatives are of great im portance.
  • the thioredoxin reductase described by Briggs et al. (WO 02/090300 A2) has an altered cofactor specificity which preferably binds NADPH compared to NADH.
  • both enzymes, the starting point as well as the resulting engineered enzyme are highly specific towards different substrates.
  • the methods to achieve such an altered substrate specificity are either computational processing methods or sequence alignments of related proteins to define variable and conserved residues. They all have in common that they are based on the comparison of structures and sequences of proteins with known specificities followed by the transfer of the same to another backbone.
  • subtilisin variants with combination mutations (N62D/G166D, and optionally Y104D) having a shift of substrate specificity towards peptide or polypeptide substrates with basic am ino acids at the P1 , P2 and P4 positions of the substrate.
  • Suitable substrates of the variant subtilisin were revealed by sorting a library of phage particles (substrate phage) containing five contiguous random ized residues.
  • subtilisin variants are useful for cleaving fusion proteins with basic substrate linkers and processing hormones or other proteins (in vitro or in vivo) that contain basic cleavage sites.
  • phage production is dependent on the cleavage of a phage protein which only can be activated in the presence of a proteolytic enzyme which is able to cleave the phage protein.
  • Other approaches use a reporter system which allows a selection by screening instead of a genetic selection, but also cannot overcome the intrinsic insufficiency of the intracellular characterization of enzymes.
  • Duff et al. (WO 98/ 1 1237) describe an expression system for a self-secreting protease.
  • An essential element of the experimental design is that the catalytic reaction acts on the protease itself by an autoproteolytic processing of the membrane-bound precursor molecule to release the matured protease from the cellular membrane into the extracellular environment. Therefore, a fusion protein m ust be constructed where the target peptide sequence replaces the natural cleavage site for autoproteolysis.
  • Lim itations of such a system are that positively identified proteases will have the ability to cleave a certain am ino acid sequence but they also may cleave many other peptide sequences. Therefore, high substrate specificity cannot be achieved. Additionally, such a system is not able to control that selected proteases cleave at a specific position in a defined am ino acid sequence and it does not allow a precise characterization of the kinetic constants of the selected proteases (k cat , K M ) .
  • a method has been described that aims at the generation of new catalytic activities and specificities within the ⁇ / ⁇ -barrel proteins (WO 01 /42432; Fersht et al, Methods of producing novel enzymes; Altam irano et al. (2000) Nature 403, 617-622) .
  • the ⁇ / ⁇ -barrel proteins com prise a large superfam ily of proteins accounting for a large fraction of all known enzymes.
  • the structure of the proteins is m ade from a/ ⁇ - barrel surrounded by ⁇ - helices.
  • the loops connecting ⁇ -strands and helices com prise the so-called lid-structure including the acitve site residues.
  • the method is based on the classification of ⁇ / ⁇ -barrel proteins into two classes based on the catalytic lid structure.
  • An extensive com parison of ⁇ / ⁇ -barrel protein structures led the authors to the conclusion that the substrate binding and specificity is primarily defined by the barrel structure while the specificity of the chem ical reaction resides within the loops. It is suggested that barrels and lid structures from different enzymes can be combined to generate new enzymatic activities and to provide a starting point to fine tune the properties by targeted or random ized m utagenesis and selection. The method does not provide for the generation of user-defined specificity.
  • the objective of the present invention is to provide a method for the treatm ent of a disease by applying a medicament com prising a protease.
  • the present invention provides engineered proteins with novel functions that do not exist in the com ponents used for the engineering of such proteins.
  • the invention provides enzymes with user-definable specificities.
  • User-definable specificity means that enzymes are provided with specificities that do not exist in the com ponents used for the engineering of such enzymes. The specificities can be chosen by the user so that one or more intended target substrates are preferentially recognised and converted by the enzymes.
  • the invention provides enzymes that possess essentially identical sequences to human proteins but have different specificities. I n a particular em bodiment, the invention provides proteases with user-definable specificities.
  • the present invention is directed to engineered enzymes which are fused to one or m ore further functional com ponents.
  • These further com ponents can be proteinacious com ponents which preferably have binding properties and are of the group consisting of substrate binding domains, antibodies, receptors or fragments thereof.
  • the engineered proteases are fused to proteins or peptide sequences that bind to marker molecules that are only present or over-expressed in specific tissues, specific organs, specific cell types, specific diseases or a combination thereof, thereby increasing the half- life of the engineered proteases or increasing the local concentration in the respective tissues, organs or diseased areas of the body.
  • the engineered proteases are fused to proteins or peptide sequences that bind to the target molecule of the engineered protease, thereby increasing the interaction between protease and target.
  • the engineered proteases are fused to proteins or peptide sequences that reduce the rate of clearance from the serum after i.v. adm inistration .
  • the engineered proteases are fused to proteins or peptide sequences that trigger the im port of the protease into target cells or the transport of the proteases across the blood brain barrier.
  • the above further com ponents can be further functional com ponents, preferably being selected from the group consisting of polyethylenglycols, carbohydrates, lipids, fatty acids, nucleic acids, metals, metal chelates, and fragments or derivatives thereof.
  • the resulting fusion proteins are understood as enzymes with user-definable specificities within the present invention.
  • the invention is directed to the application of such enzymes with novel, user-definable specificities for therapeutic, research, diagnostic, nutritional, personal care or industrial purposes. Moreover, the invention is directed to a method for generating engineered enzymes with user-definable specificities. I n particular, the invention is directed to generate enzymes that possess essentially identical sequences to hum an enzymes but have different specificities. This problem has been solved by the embodiments of the invention specified in the description below and in the claims. The present invention is thus directed to
  • SDRs specificity determ ining regions located at sites in the protein scaffold that enable the resulting engineered protein to discrim inate between at least one target substrate and one or more different substrates, and herein the SDRs are essentially synthetic peptide sequences;
  • step (b) generating a library of engineered enzym es by com bining the protein scaffold from step (a) with fully or partially random peptide sequences at sites in the protein scaffold that enable the resulting engineered enzyme to discrim inate between at least one target substrate and one or m ore different substrates, and
  • step (c) selecting out of the library of engineered enzymes generated in step (b) one or more enzym es that have specificities towards at least one target substrate;
  • fusion protein which is com prised of at least one engineered enzyme as defined in (2) above and at least one further com ponent, preferably the at least one further com ponent having binding properties and more preferably being selected from the group consisting of antibodies, binding domains, receptors, and fragments thereof;
  • Figure 1 illustrates the three-dimensional structure of human trypsin I with the active site residues shown in "ball-and-stick” representation and with the marked regions indicating potential SDR insertion sites.
  • Figure 2 shows the alignm ent of the primary am ino acid sequence of three members of the serine protease class S1 fam ily: human trypsin I , human alpha- thrombin and human enteropeptidase (see also SEQ I D NOs: 1 , 5 and 6) .
  • Figure 3 illustrates the three-dimensional structure of subtilisin with the active site residues being shown in "ball-and-stick" representation and with the numbered regions indicating potential SDR insertion sites.
  • Figure 4 shows the alignment of the primary am ino acid sequences of four members of the serine protease class S8 fam ily: subtilisin E, furin, PC1 and PC5 (see also SEQ I D NOs: 7-1 0) .
  • Figure 5 illustrates the three-dimensional structure of pepsin with the active site residues being shown in "ball-and-stick" representation and with the numbered regions indicating potential SDR insertion sites.
  • Figure 6 shows the alignm ent of the prim ary am ino acid sequences of three members of the A1 aspartic acid protease fam ily: pepsin, ⁇ -secretase and cathepsin D (see also SEQ I D NOs: 1 1 -13) .
  • Figure 7 illustrates the three-dimensional structure of caspase 7 with the active site residues being shown in "ball-and-stick" representation and with the numbered regions indicating potential SDR insertion sites.
  • Figure 8 shows the primary am ino acid sequence of caspase 7 as a member of the cysteine protease class C14 fam ily (see also SEQ I D NO: 14) .
  • Figure 9 depicts schematically the third aspect of the invention.
  • Figure 1 0 shows a Western blot analysis of a culture supernatant of cells expressing variants of hum an trypsin I with SDR1 and SDR2, com pared to negative controls.
  • Figure 1 1 shows the time course of the proteolytic cleavage of a target substrate by human trypsin I .
  • Figure 12 shows the relative activities of three variants of inventive engineered proteolytic enzymes in com parison with human trypsin I on two different peptide substrates.
  • Figure 13 shows the relative specificities of human trypsin I and variants of inventive engineered proteolytic enzymes with one or two SDRs, respectively.
  • Figure 14 shows the relative specificities of human trypsin I and of variants of inventive engineered proteolytic enzymes being specific for human TNF-alpha with this scaffold on peptides with a target sequence of human TNF-alpha.
  • Figure 15 shows the reduction of cytotoxicity induced by TNF-alpha when incubating the TNF-alpha with concentrated supernatant from cultures expressing the inventive engineered proteolytic enzymes being specific for human TNF-alpha.
  • Figure 16 shows the reduction of cytotoxicity induced by TNF-alpha when incubating the TNF-alpha with purified inventive engineered proteolytic enzyme being specific for human TNF-alpha.
  • Figure 17 com pares the activity of inventive engineered proteolytic enzymes being specific for human TNF-alpha with the activity of human trypsin I on two protein substrates: (a) human TNF-alpha; (b) m ixture of human serum proteins.
  • Figure 18 showes the specific activity of an inventive engineered proteolytic enzym e with specificity for human VEGF.
  • proteases means any protein molecule that is capable of hydrolysing peptide bonds. This includes naturally-occurring or artificial proteolytic enzymes, as well as variants thereof obtained by site-directed or random m utagenesis or any other protein engineering method, any active fragment of a proteolytic enzym e, or any molecular com plex or fusion protein com prising one of the aforementioned proteins.
  • a "chimera of proteases” means a fusion protein of two or m ore fragments derived from different parent proteases.
  • substrate m eans any molecule that can be converted catalytically by an enzyme.
  • peptide substrate m eans any peptide, oligopeptide, or protein molecule of any am ino acid com position, sequence or length, that contains a peptide bond that can be hydrolyzed catalytically by a protease.
  • the peptide bond that is hydrolyzed is referred to as the "cleavage site” . Numbering of positions in the substrate is done according to the system introduced by Schlechter & Berger ( Biochem . Biophys. Res. Com m un. 27 ( 1 967) 157-162) .
  • Am ino acid residues adj acent N-term inal to the cleavage site are numbered R , P 2 , P 3 , etc.
  • residues adjacent C-term inal to the cleavage site are numbered P 1 ', P 2 ', P 3 ', etc.
  • target substrate describes a user-defined substrate which is specifically recognized and converted by an enzyme according to the invention.
  • target peptide substrate describes a user-defined peptide substrate.
  • target specificity describes the qualitative and quantitative specificity of an enzyme that is capable of recognizing and converting a target substrate.
  • Catalytic properties of enzymes are expressed using the kinetic param eters " K M " or “Michaelis Menten constant”, “k cat “ or “catalytic rate constant”, and “k cat / K M “ or “catalytic efficiency”, according to the definitions of Michaelis and Menten ( Fersht, A. , Enzyme Structure and Mechanism , W. H. Freem an and Com pany, New York, 1995) .
  • the term “catalytic activity” describes quantitatively the conversion of a given substrate under defined reaction conditions.
  • the term "specificity” means the ability of an enzym e to recognize and convert preferentially certain substrates. Specificity can be expressed qualitatively and quantitatively. “Qualitative specificity” refers to the chem ical nature of the substrate residues that are recognized by an enzyme. “Quantitative specificity” refers to the number of substrates that are accepted as substrates. Quantitative specificity can be expressed by the term s, which is defined as the negative logarithm of the number of all accepted substrates divided by the num ber of all possible substrates. Proteases, for exam ple, that accept preferantially a small portion of all possible peptide substrates have a "high specificity” .
  • Proteases that accept almost any peptide substrate have a "low specificity” . Definitions are made in accordance to WO 03/095670 which is therefore incorporated by reference. Proteases with very low specificity are also referred to as “unspecific proteases” .
  • the term "defined specificity” refers to a certain type of specificity, i.e. to a certain target subtrate or a set of certain target substrates that are preferentially converted versus other substrates.
  • protein scaffold or "scaffold protein” refers to a variety of primary, secondary and tertiary polypeptide structures.
  • peptide sequence indicates any peptide sequence used for insertion or substitution into or combination with a protein scaffold.
  • Peptide sequences are usually obtained by expression from DNA sequences which can be synthesized according to well-established techniques or can be obtained from natural sources. I nsertion, substitution or combination of peptide sequences with the protein scaffold are generated by insertion, substitution or combination of oligonucleotides into or with a polynucleotide encoding the protein scaffold.
  • synthetic in combination with the term “peptide sequence” refers to peptide sequences that are not present in the protein scaffold in which the peptide sequences are inserted or substituted or with which they are combined.
  • ком ⁇ онентs in combination with the term “engineered enzyme” refers to peptide or polypeptide sequences that are combined in the engineering of such enzymes. Such com ponents may among others com prise one or more protein scaffolds and one or more synthetic peptide sequences.
  • library of engineered enzymes describes a m ixture of engineered enzymes, whereby every single engineered enzyme is encoded by a different polynucleotide sequence.
  • gene library indicates a library of polynucleotides that encodes the library of engineered enzymes.
  • SDR Specificity determ ining region
  • SDR sites refers to a synthetic peptide sequence that provides the defined specificity when combined with the protein scaffold at sites that enable the resulting enzymes to discrim inate between the target substrate and one or more other substrates. Such sites are termed "SDR sites”.
  • positions that correspond structurally indicates amino acids in proteins of similar tertiary structure that correspond structurally to each other, i.e. they are usually located within the same structural or topological element of the structure. Within the structural element they possess the same relative positions with respect to beginning and end of the structural element. If, e.g. the topological comparison of two proteins reveals two structurally corresponding sequences of different length, then amino acids within, e.g. 20% and 40% of the respective region lengths, correspond to each other structurally.
  • library of engineered enzymes refers to a multiplicity of enzymes or enzyme variants, which may exist as a mixture or in isolated form.
  • the present invention provides engineered proteins with novel functions.
  • the invention provides enzymes with user-definable specificities.
  • the invention provides proteases with user-definable specificities.
  • the invention provides applications of such enzymes with novel, user-definable specificities for therapeutic, research, diagnostic, nutritional, personal care or industrial purposes.
  • the invention provides a method for generating enzymes with specificities that are not present in the com ponents used for the engineering of such enzym es.
  • the invention is directed to the generation of enzymes that have sequences that are essentially identical to mam malian, especially human enzymes but have different specificities .
  • the invention provides libraries of specific engineered enzymes with corresponding specificities encoded genetically, a method for the generation of libraries of specific engineered enzymes with corresponding specificities encoded genetically, and the application of such libraries for technical, diagnostic, nutritional, personal care or research purposes.
  • a first aspect of the invention is directed to the application of engineered enzymes with specificities for therapeutic, research, diagnostic, nutritional, personal care or industrial purposes.
  • the application com prises at least the following steps:
  • step (b) provision of an engineered enzyme, the enzyme being specific for the target peptide identified in step (a) ;
  • step (c) use of the enzym e as provided in step (b) for the intended purpose.
  • the engineered enzym e is used as a therapeutic means to inactivate a disease- related target substrate.
  • This application com prises at least the following steps:
  • step (b) provision of an engineered enzyme, the enzyme being specific for the target site identified in step (a) ;
  • the scaffold is a protease and the modification is hydrolysis of a target site in a protein target.
  • the hydrolysis leads to the activation or inactivation of the peptide or protein target.
  • Potential peptide or protein targets include soluble proteins, in particular cytokines, such as proteins of the TNF- superfamily , interleukines, interferons, chemokines and growth factors; hormones; toxins; enzymes, such as oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases; structural proteins, such as collagen; im m unoglobulins; activity modulating proteins and DNA binding proteins; or membrane associated proteins, in particular single pass transmembrane proteins; m ultipass transmembrane proteins, such as G- protein coupled receptors, ion channels and transporters; lipid-anchored membrane proteins and GPI-anchored membrane proteins.
  • the engineered enzyme is a protease and is capable of hydrolysing human tumor necrosis factor-alpha (hTNF- ⁇ ) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, rheumatoid arthritis, inflam matory bowel diseases, psoriasis, Crohn's disease, Ulcerative colitis, diabetes type I I , classical Hodgkin's Lym phoma (cHL) , Grave's disease, Hashimoto's thyroiditis, Sjogren's Syndrome, system ic lupus erythematosus, m ultiple sclerosis, System ic inflam matory response syndrome (SI RS) which leads to distant organ damage and m ultiple organ dysfunction syndrome ( MODS) , eosinophilia, neurodegenerative disease, stroke, closed head injury, encephalitis
  • diseases such as, but
  • said enzyme or said fusion protein is capable of specifically inactivating hTNF- ⁇ (SEQ I D NO: 96) . More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 31 /32, 32/33, 44/45, 45/46, 87/88, 128/ 129, 130/ 131 , 140/ 141 and/or 141 / 142 (most preferred between positions 31/32, 32/33 and/or 45/46) in hTNF- ⁇ , or a peptide bond in proximity to these positions in hTNF- ⁇ , or peptide bonds in protein targets related to hTNF- ⁇ between positions having structural homology or sequence homology to these positions.
  • the protease has the a sequence shown in SEQ ID NO:74, SEQ ID NO:75 and is capable of hydrolysing hTNF- ⁇ at positions 31/32 and/or 32/33.
  • the enzyme is a protease and is capable of hydrolysing human Tumor necrosis factor ligand superfamily member 5 (hCD40-L).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, systemic lupus erythematosus and classical Hodgkin's Lymphoma (cHL), as well as other diseases connected with hCD40-L.
  • said enzyme or said fusion protein is capable of specifically inactivating hCD40-L (SEQ ID NO: 143).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 133/134, 145/146, 165/166, 200/201, 201/202, 207/208 and/or 216/217 (most preferred between positions 133/134, 165/166, 201/202 and/or 216/217) in hCD40-L, or a peptide bond in proximity to these positions in hCD40-L, or peptide bonds in protein targets related to hCD40-Lat positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Macrophage migration inhibitory factor (hMIF).
  • hMIF human Macrophage migration inhibitory factor
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammatory diseases, as well as other diseases connected with hMIF.
  • said enzyme or said fusion protein is capable of specifically inactivating hMIF (SEQ ID NO: 109).
  • said engineered or said fusion protein is capable of hydrolysing the peptide bonds between positions 16/17, 44/45, 66/67, 73/74, 77/78, 88/89, 92/93 and/or 100/101 (most preferred between positions 16/17 and/or 92/93) in hMIF, or a peptide bond in proximity to these positions in hMIF, or peptide bonds in protein targets related to hMIF at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human I nterleukin- 1 beta precursor (hlL-1 beta).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, diabetes, brain inflammation in cancer, arthritis, autoimmune and inflammatory diseases, as well as other diseases connected with hlL-1 beta.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-1 beta (SEQ ID NO: 112).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 24/25, 35/36, 46/47, 54/55, 74/75, 75/76, 76/77, 77/78, 86/87, 88/89, 93/94, 94/95, 97/98 and/or 150/151 (most preferred between positions 35/36, 75/76, 76/77, 88/89, 93/94, 94/95 and/or 150/151) in hlL-1 beta, or a peptide bond in proximity to these positions in hlL-1 beta, or peptide bonds in protein targets related to hlL-1 beta at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 2 (hlL-2).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, T-cell leukemia and hairy cell leukemia, Crohn's disease, Ulcerative colitis, Grave's disease, Hashimoto's thyroiditis, Sjogren's syndrome, systemic lupus erythematosus, multiple sclerosis, asthma and chronic obstructive pulmonary and classical Hodgkin's Lymphoma (cHL), as well as other diseases connected with hlL-2.
  • diseases such as, but not limited to, T-cell leukemia and hairy cell leukemia, Crohn's disease, Ulcerative colitis, Grave's disease, Hashimoto's thyroiditis, Sjogren's syndrome, systemic lupus erythematosus, multiple sclerosis, asthma and chronic o
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-2 (SEQ ID NO: 99). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 20/21, 32/33, 38/39, 43/44, 45/46 48/49, 49/50, 54/55, 64/65, 76/77, 83/84, 84/85, 107/108, 109/110 and/or 120/121 (most preferred between positions 109/110) in hlL-2, or a peptide bond in proximity to these positions in hlL-2, or peptide bonds in protein targets related to hlL-2 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 3 (hlL-3).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL) and eosinophilia, as well as other diseases connected withh IL-3.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-3 (SEQ ID NO: 148).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 21/22, 28/29, 36/37, 44/45, 46/47, 51/52, 63/64, 66/67, 79/80, 94/95, 101/102, 108/109 and/or 109/110 (most preferred between positions 21/22, 28/29, 46/47, 63/64, 66/67, 79/80 and/or 101/102) in hlL-3, or a peptide bond in proximity to these positions in hlL-3, or peptide bonds in protein targets related to hlL-3 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 4 (hlL-4).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL), Grave's disease, Hashimoto's thyroiditis, Sjogren's syndrome, Asthma, chronic obstructive pulmonary disease and allergic inflammatory reactions, as well as other diseases connected with hlL-4.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-4 (SEQ ID NO: 118).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 4/5, 12/13, 31/32, 37/38, 61/62, 62/63, 64/65, 91/92, 102/103, 121/122 and/or 126/127 (most preferred between positions 4/5, 61/62, 62/63, 64/65 and/or 121/122) in hlL-4, or a peptide bond in proximity to these positions in hlL-4, or peptide bonds in protein targets related to hlL-4 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin-5 (hlL-5).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL), asthma, chronic obstructive pulmonary disease, eosinophilia, allergic inflammatory diseases, as well as other diseases connected with hlL-5.
  • diseases such as, but not limited to, classical Hodgkin's Lymphoma (cHL), asthma, chronic obstructive pulmonary disease, eosinophilia, allergic inflammatory diseases, as well as other diseases connected with hlL-5.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-5 (SEQ ID NO: 133).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 12/13, 32/33, 67/68, 76/77, 77/78, 80/81, 83/84, 84/85, 85/86, 90/91, 91/92, 92/93 and/or 98/99 (most preferred between positions 90/91, 91/92, 92/93 and/or 98/99) in hlL-5, or a peptide bond in proximity to these positions in hlL-5, or peptide bonds in protein targets related to hlL-5 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin-6 (hlL-6).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL), breast cancer, renal cell carcinoma, multiple myeloma, lymphoma, leukemia, Grave's disease, Hashimoto's thyroiditis, Sjogren's syndrome, systemic lupus erythematosus, Systemic inflammatory response syndrome (SIRS) which leads to distant organ damage and multpile organ dysfunction syndrome (MODS), chronic obstructive pulmonary disease (COPD), Castleman's diseases, inflammatory bowel diseases, Crohn's disease, as well as other diseases connected with hlL-6.
  • diseases such as, but not limited to, classical Hodgkin's Lymphoma (cHL), breast cancer, renal cell carcinoma, multiple myeloma, lymph
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-6 (SEQ ID NO: 134). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 32/33, 35/36, 55/56, 71/72, 129/130, 130/131, 132/133, 135/136, 141/142, 161/162, 180/181 and/or 183/184 (most preferred between positions 135/136 and/or 141/142) in hlL-6, or a peptide bond in proximity to these positions in hlL-6, or peptide bonds in protein targets related to hlL-6 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 8 (hlL-8).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, Crohn's disease, Ulcerative colitis, classical Hodgkin's Lymphoma (cHL), Systemic inflammatory response syndrome (SIRS) which leads to distant organ damage and multple organ dysfunction syndrome (MODS), chronic obstructive pulmonary disease (COPD), endometriosis, psoriasis and atherosclerotic lesions, as well as other diseases connected with hlL-8.
  • diseases such as, but not limited to, Crohn's disease, Ulcerative colitis, classical Hodgkin's Lymphoma (cHL), Systemic inflammatory response syndrome (SIRS) which leads to distant organ damage and multple organ dysfunction syndrome (MODS), chronic obstructive pulmonary disease (COPD), endometriosis,
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-8 (SEQ ID NO: 100). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1/12, 15/16, 45/46, 47/48, 52/53, 54/55, 60/61, 64/65 and/or 67/68 (most preferred between positions 45/46) in hlL-8, or a peptide bond in proximity to these positions in hlL-8, or peptide bonds in protein targets related to hlL-8 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin- 10 (hi L- 10).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL) and diseases related to the suppression of cytotoxic T-cells, as well as other diseases connected with hi L- 10.
  • diseases such as, but not limited to, classical Hodgkin's Lymphoma (cHL) and diseases related to the suppression of cytotoxic T-cells, as well as other diseases connected with hi L- 10.
  • said enzyme or said fusion protein is capable of specifically inactivating hi L- 10 (SEQ ID NO: 135).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 24/25, 25/26, 27/28, 28/29, 40/41, 44/45, 49/50, 57/58, 59/60, 84/85, 86/87, 106/107, 107/108, 110/111, 130/131, 134/135, 137/138, 138/139 and/or 144/145 (most preferred between positions 24/25, 27/28, 44/45, 49/50, 86/87, 137/138 and/or 144/145) in hi L- 10, or a peptide bond in proximity to these positions in hi L- 10, or peptide bonds in protein targets related to hi L- 10 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 12 beta chain (hi L- 12 ⁇ ) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, Crohn's disease and classical Hodgkin's Lymphoma (cHL), as well as other diseases connected with hi L- 12 ⁇ .
  • said enzyme or said fusion protein is capable of specifically inactivating hi L- 12 ⁇ (SEQ ID NO: 97).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 14/15, 18/19, 29/30, 34/35, 87/88, 99/100, 102/103, 104/105, 161/162, 174/175, 222/223, 225/226, 228/229, 238/239, 268/269 and/or 293/294 (most preferred between positions 18/19, 34/35, 87/88 and/or 161/162) in hi L- 12 ⁇ , or a peptide bond in proximity to these positions in h I L- 12 ⁇ , or peptide bonds in protein targets related to hi L- 12 ⁇ at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 13 (hi L- 13).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of cancer, such as, but not limited to, classical Hodgkin's Lymphoma (cHL), eosinophilia, asthma, chronic obstructive pulmonary disease, fibrosis, psoriasis, atopic dermatitis and Ulcerative colitis, as well as other diseases connected with hlL-13.
  • said enzyme or said fusion protein is capable of specifically inactivating hi L- 13 (SEQ ID NO: 119).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 25/26, 62/63, 65/66, 86/87, 87/88, 98/99, 108/109 and/or 111/112 (most preferred between positions 87/88) in hi L- 13, or a peptide bond in proximity to these positions in hi L- 13, or peptide bonds in protein targets related to hi L- 13 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lnterleukin 18 (hi L- 18).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, Crohn's disease, inflammation liver injuries, pulmonary tuberculosis, plural tuberculosis and rheumatoid arthritis, as well as other diseases connected with hi L- 18.
  • said enzyme or said fusion protein is capable of specifically inactivating hi L- 18 (SEQ ID NO:98).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 17/18, 32/33, 37/38, 39/40, 40/41, 53/54, 58/59, 79/80, 90/91, 93/94, 98/99, 110/111, 120/121, 123/124, 131/132, 132/133, 142/143, 147/148 and/or 157/158 (most preferred between positions 37/38, 132/133, 142/143 and/or 157/158) in hi L- 18, or a peptide bond in proximity to these positions in hi L- 18, or peptide bonds in protein targets related to hi L- 18 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Interferon-gamma (hlFN-gamma).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL), Crohn's disease and type I diabetes, as well as other diseases connected with hlFN-gamma.
  • said enzyme or said fusion protein is capable of specifically inactivating hlFN-gamma (SEQ ID NO: 137).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 2/3, 6/7, 13/14, 21/22, 24/25, 34/35, 36/37, 37/38, 62/63, 68/69, 83/84, 86/87, 90/91, 102/103, 107/108 and/or 108/109 (most preferred between positions 13/14, 24/25, 37/38, 62/63, 68/69, 102/103 and/or 107/108) in hlFN-gamma, or a peptide bond in proximity to these positions in hlFN-gamma, or peptide bonds in protein targets related to hlFN-gamma at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human small inducible cytokine A2 (hCCL2).
  • hCCL2 human small inducible cytokine A2
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, Crohn's disease and Ulcerative colitis, as well as other diseases connected with hCCL2.
  • said enzyme or said fusion protein is capable of specifically inactivating hCCL2 (SEQ ID NO: 102).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 3/4, 13/14, 18/19, 19/20, 24/25, 29/30, 38/39, 54/55, 56/57, 58/59, 62/63, 65/66 and/or 68/69 (most preferred between positions 19/20, 29/30, 38/39, 54/55 and/or 62/63) in hCCL2, or a peptide bond in proxim ity to these positions in hCCL2, or peptide bonds in protein targets related to hCCL2 at positions having structural hom ology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Eotaxin (hCCL1 1 ) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, Crohn's disease and Ulcerative colitis, classical Hodgkin's Lym phom a (cHL) , chronic pathophysiologic dysfunction, characterized by an influx mainly of Th2 cells, and eosinophilia, as well as other diseases connected with hCCL1 1 .
  • diseases such as, but not lim ited to, Crohn's disease and Ulcerative colitis, classical Hodgkin's Lym phom a (cHL) , chronic pathophysiologic dysfunction, characterized by an influx mainly of Th2 cells, and eosinophilia, as well as other diseases connected with hCCL1 1 .
  • said enzym e or said fusion protein is capable of specifically inactivating hCCL1 1 (SEQ I D NO: 1 01 ) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1 1 / 12, 16/ 1 7, 1 7/ 18, 22/23, 27/28, 33/34, 44/45, 47/48, 48/49, 52/53, 54/55, 56/57, 60/61 , 66/67 and/or 73/74 (most preferred between positions 48/49 and/or 66/67) in hCCL1 1 , or a peptide bond in proxim ity to these positions in hCCL1 1 , or peptide bonds in protein targets related to hCCL1 1 at positions having structural homology or sequence homology to these positions.
  • the enzym e is a protease and is capable of hydrolysing human Vascular endothelial growth factor (hVEGF) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, all solid tumors and metastatic solid tumors, inflam m atory breast cancer, as well as other diseases connected with hVEGF.
  • said enzyme or said fusion protein is capable of specifically inactivating hVEGF (SEQ I D NO: 103) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1 6/ 1 7, 19/20, 23/24, 34/35, 41 /42, 56/57, 62/63, 63/64, 64/65, 65/66, 82/83, and/or 84/85 (most preferred between positions 23/24, 41 /42, 63/64, 82/83 and/or 84/85) in hVEGF, or a peptide bond in proximity to these positions in hVEGF, or peptide bonds in protein targets related to hVEGF at positions having structural homology or sequence homology to these positions.
  • the enzym e is a protease and is capable of hydrolysing human Transform ing growth factor beta 1 (hTGF- ⁇ 1 ) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatm ent of diseases, such as, but not lim ited to, a variety of cancers, including breast cancer, colorectal cancer and classical Hodgkin's Lym phom a (cHL) , fibrosis, suppression of cell- mediated immunity, glaucoma, diffuse systemic sclerosis as well as other diseases connected with hTGF- ⁇ 1.
  • diseases such as, but not lim ited to, a variety of cancers, including breast cancer, colorectal cancer and classical Hodgkin's Lym phom a (cHL) , fibrosis, suppression of cell- mediated immunity, glaucoma, diffuse systemic sclerosis as well as other diseases connected with hTGF- ⁇ 1.
  • said enzyme or said fusion protein is capable of specifically inactivating hTGF- ⁇ 1 (SEQ ID NO: 104). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 23/24, 25/26, 26/27, 27/28, 37/38, 55/56 and/or 94/95 (most preferred between positions 25/26, 55/56 and/or 94/95) in hTGF- ⁇ 1, or a peptide bond in proximity to these positions in hTGF- ⁇ 1 , or peptide bonds in protein targets related to hTGF- ⁇ 1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Somatotropin (human Growth hormone; hGH).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, acromegaly, diabetes and diabetic kidney disease including renal hypertrophy and glomerular enlargement and cardiovascular disorders, as well as other diseases connected with hGH.
  • said enzyme or said fusion protein is capable of specifically inactivating hGH (SEQ ID NO: 121).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 16/17, 19/20, 26/27, 33/34, 38/39, 41/42, 70/71, 77/78, 94/95, 103/104, 112/113, 115/116, 116/117, 130/131, 147/148, 154/155 and/or 178/179 (most preferred between positions 112/113, 147/148 and/or 154/155) in hGH, or a peptide bond in proximity to these positions in hGH, or peptide bonds in protein targets related to hGH at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Insulin-like growth factor Il (hlGF-ll).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, diabetes and diabetic kidney disease, as well as other diseases connected with hlGF-ll.
  • said enzyme or said fusion protein is capable of specifically inactivating hlGF-ll (SEQ ID NO:122).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 15/16, 23/24, 24/25, 34/35, 37/38, 38/39, 48/49 and/or 49/50 (most preferred between positions 23/24) in hlGF-ll, or a peptide bond in proximity to these positions in hlGF-ll, or peptide bonds in protein targets related to hlGF-ll at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Hepatocyte growth factor (hHGF) .
  • the enzym es or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, angiogenic disorders and hepatocellular carcinoma, as well as other diseases connected with hHGF.
  • said enzyme or said fusion protein is capable of specifically inactivating hHGF (SEQ I D NO: 120) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 54/55, 60/61 , 62/63, 63/64, 68/69, 76/77, 1 12/ 1 13, 123/ 124, 134/ 135, 168/ 1 69, 198/ 199 and/or 202/203 (m ost preferred between positions 63/64, 68/69, 76/77, 1 68/ 169 and/or 202/203) in hHGF, or a peptide bond in proxim ity to these positions in hHGF, or peptide bonds in protein targets related to hHGF at positions having structural hom ology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human hi nsulin (hl nsulin) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, insulin overdosage, as well as other diseases connected with hl nsulin.
  • said enzyme or said fusion protein is capable of specifically inactivating hl nsulin B chain (SEQ I D NO: 105) and/or hl nsulin A chain (SEQ I D NO: 106) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 16/ 17 and/or 22/23 in hl nsulin B and/or between position 14/ 15 in I nsulin A, or a peptide bond in proxim ity to these positions in hl nsulin A or B, or peptide bonds in protein targets related to hl nsulin A or B at positions having structural hom ology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human hGhrelin (hGhrelin) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, obesity, as well as other diseases connected with hGhrelin.
  • said enzyme or said fusion protein is capable of specifically inactivating hGhrelin (SEQ I D NO: 107) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1 /2, 2/3, 3/4 and/or 4/5 in hGhrelin, or a peptide bond in proximity to these positions in hGhrelin, or peptide bonds in protein targets related to hGhrelin at positions having structural homology or sequence hom ology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human angiotensinogen (angiotensin) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, essential hypertension, as well as other diseases connected with angiotensin.
  • said enzyme or said fusion protein is capable of specifically inactivating angiotensin (SEQ I D NO: 108) .
  • said enzym e or said fusion protein is capable of hydrolysing the peptide bonds between positions 1 /2, 3/4 and/or 7/8 (m ost preferred between positions 3/4) in angiotensin, or a peptide bond in proxim ity to these positions in angiotensin, or peptide bonds in protein targets related to angiotensin at positions having structural homology or sequence hom ology to these positions.
  • the enzyme is a protease and is capable of hydrolysing hum an leptin precursor (leptin) .
  • the enzym es or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, obesity, as well as other diseases connected with leptin .
  • said enzyme or said fusion protein is capable of specifically inactivating leptin (SEQ I D NO: 127) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 9/ 10, 15/ 16, 23/24, 40/41 , 53/54, 71 /72, 85/86, 94/95, 1 08/ 1 09 and/or 141 / 142 (most preferred between positions 9/ 1 0, 40/41 , 71 /72, 94/95 and/or 108/ 109) in leptin, or a peptide bond in proxim ity to these positions in leptin, or peptide bonds in protein targets related to leptin at positions having structural homology or sequence hom ology to these positions.
  • the enzym e is a protease and is capable of hydrolysing Protective antigen ( PA-83) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, ant hrax infection, as well as other diseases connected with PA-83.
  • said enzyme or said fusion protein is capable of specifically inactivating PA-83 (SEQ I D NO: 123) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 72/73, 73/74, 92/93, 93/94, 131 / 132, 149/ 150, 178/ 1 79, 213/214, 214/215, 387/388, 425/426, 426/427, 427/428, 453/454, 520/521 , 608/609, 617/61 8, 671 /672, 679/680, 680/681 , 683/684 and/or 684/685 (m ost preferred between positions 72/73, 73/74, 93/94, 149/ 1 50, 387/388, 425/426, 427/428 and/or 683/684) in PA- 83, or a peptide bond in proxim ity to these positions in PA-83, or peptide bonds in protein targets related to PA-83 at positions having structural homology or sequence hom ology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human plasm inogen (plasm inogen) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, thrombosis, as well as other diseases connected with plasm inogen .
  • said enzyme or said fusion protein is capable of specifically inactivating plasm inogen (SEQ I D NO: 140) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bond between position 580/581 in plasm inogen, or a peptide bond in proxim ity to this position in plasm inogen, or peptide bonds in protein targets related to plasm inogen at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Prothrombin (thrombin) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, bleeding, as well as other diseases connected with thrombin.
  • said enzyme or said fusion protein is capable of specifically inactivating throm bin (SEQ I D NO: 149) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 198/ 199, 327/328, 363/364 (most preferred between positions 327/328 and/or 363/364) in thrombin, or a peptide bond in proxim ity to these positions in thrombin, or peptide bonds in protein targets related to throm bin at positions having structural hom ology or sequence homology to these positions
  • the enzyme is a protease and is capable of hydrolysing human beta-secretase.
  • the enzymes or the fusion protein can thus be used for preparing medicam ents for the treatment of diseases, such as, but not lim ited to, Alzheimer, as well as other diseases connected with human beta- secretase precursor.
  • said enzyme or said fusion protein is capable of specifically inactivating human beta-secretase precursor (SEQ I D NO: 139) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 61 /62, 64/65, 159/ 1 60, 238/239, 239/240, 246/247, 256/257, 330/331 and/or 365/366 (most preferred between positions 61 /62, 246/247 and/or 365/366) in hum an beta-secretase precursor, or a peptide bond in proxim ity to these positions in human beta-secretase precursor, or peptide bonds in protein targets related to human beta-secretase precursor at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human matrix metalloproteinase-2 (hMMP-2).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, a variety of cancers including bladder cancer, breast tumor cancer, gastric cancer and lung cancer, as well as other diseases connected with hMMP-2.
  • said enzyme or said fusion protein is capable of specifically inactivating hMMP-2 (SEQ ID NO: 131).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 62/63, 68/69, 75/76, 76/77, 79/80, 88/89, 110/111, 112/113, 115/116, 120/121, 164/165, 254/255, 267/268, 296/297, 324/325, 325/326, 382/383, 383/384, 470/471, 500/501, 550/551, 564/565, 595/596, 597/598, 608/609, 646/647, 649/650 and/or 650/651 (most preferred between positions 68/69, 115/116, 120/121, 164/165, 325/326, 383/384, 470/471, 500/501, 595/596, 608/609 and/or 650/651) in hMMP-2, or a peptide bond in proximity to these positions in hMMP-2, or peptide bonds in protein targets related to hMMP
  • the enzyme is a protease and is capable of hydrolysing human matrix metalloproteinase-9 (hMMP-9).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, a variety of cancers including bladder cancer, breast tumor cancer, gastric cancer and lung cancer, as well as other diseases connected with hMMP-9.
  • said enzyme or said fusion protein is capable of specifically inactivating hMMP-9 (SEQ ID NO: 132).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 41/42, 42/43, 106/107, 113/114, 134/135, 160/161, 162/163, 163/164, 222/223, 226/227, 265/266, 266/267, 267/268, 284/285, 309/310, 321/322, 322/323, 324/325, 356/357, 380/381, 433/434 and/or 440/441 (most preferred between positions 160/161, 163/164, 226/227, 284/285, 321/322, 322/323 and/or 433/434) in hMMP-9, or a peptide bond in proximity to these positions in hMMP-9, or peptide bonds in protein targets related to hMMP-9 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing HIV membrane glycoprotein (GP120).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, AI DS or HIV infection, as well as other diseases connected with GP120 or HI V infection.
  • said enzyme or said fusion protein is capable of specifically inactivating GP120 (SEQ I D NO: 124) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 97/98, 99/ 1 00, 107/ 108, 1 13/ 1 14, 1 17/ 1 18, 227/228, 231 /233, 279/280, 335/336, 337/338, 368/369, 412/413, 419/420, 429/430, 444/445, 457/458, 474/475, 476/477, 477/478, 485/486 and/or 490/491 (most preferred between positions 99/ 100, 368/369, 412/413, 419/420, 444/445 and/or 490/491 ) in GP120, or a peptide bond in proxim ity to these positions in GP120, or peptide bonds in protein targets related to GP120 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Cytotoxic T lym phocyte protein 4 (hCTLA-4) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, breast cancer, as well as other diseases connected with hCTLA-4.
  • said enzyme or said fusion protein is capable of specifically inactivating hCTLA-4 (SEQ I D NO: 144) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 14/ 15, 28/29, 33/34, 38/39, 41 /42, 62/63, 72/73, 85/86, 95/96, 100/ 101 , 1 05/ 106, 1 19/ 120, 125/ 126 and/or 127/ 128 (m ost preferred between positions 14/ 1 5, 28/29, 38/39, 41 /42, 62/63 and/or 85/86) in hCTLA-4, or a peptide bond in proxim ity to these positions in hCTLA-4, or peptide bonds in protein targets related to hCTLA-4 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human l ntegrin alpha-2 (hVLA-2) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, renal tumors, uveal melanomas and gastrointestinal tumors, as well as other diseases connected with hVLA-2.
  • said enzyme or said fusion protein is capable of specifically inactivating hVLA-2 (SEQ I D NO: 147) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 160/ 161 , 174/ 1 75, 201 /202, 219/220, 231 /232, 232/233, 233/234, 243/244, 259/260, 264/265, 268/269, 288/289, 292/293, 294/295, 298/299, 301 /302, 310/31 1 and/or 317/318 (most preferred between positio ns 160/ 1 61 , 174/ 1 75, 201 /202, 219/220, 243/244, 264/265, 292/293 and/or 294/295) in hVLA-2, or a peptide bond in proxim ity to these positions in hVLA-2, or peptide bonds in protein targets related to hVLA-2 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Vascular endothelial growth factor receptor 1 (hVEGFR 1 ) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, solid tumors and metastatic solid tumors, astrocytic brain tumors, pancreatic cancer, metastatic renal cancer, m etastatic solid tum ors, as well as other diseases connected with hVEGFR 1 .
  • said enzyme or said fusion protein is capable of specifically inactivating hVEGFR 1 (SEQ I D NO: 1 14) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 189/ 190, 1 90/ 1 91 , 224/225 and/or 331 /332 (m ost preferred between positions 1 89/ 190 and/or 331 /332) in hVEGFR 1 , or a peptide bond in proxim ity to these positions in hVEGFR 1 , or peptide bonds in protein targets related to hVEGFR 1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Vascular endothelial growth factor receptor 2 (hVEGFR 2) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, solid tumors and metatstatic solid tumors, pancreatic cancer, metastatic renal cancer, metastatic CRC, as well as other diseases connected with hVEGFR 2.
  • said enzyme or said fusion protein is capable of specifically inactivating hVEGFR 2 (SEQ I D NO: 1 15) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 214/215, and/or 323/324 (most preferred between position 214/215) in hVEGFR 2, or a peptide bond in proxim ity to these positions in hVEGFR 2, or peptide bonds in protein targets related to hVEGFR 2 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Epidermal growth factor receptor (hEGFr) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of disesaes, such as, but not lim ited to , bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, oesophageal cancer, head and neck cancer, gastric cancer, non-small-cell lung carcinoma and ovarian cancer, as well as other diseases connected with hEGFr.
  • said enzyme or said fusion protein is capable of specifically inactivating hEGFr (SEQ I D NO: 1 16) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 20/21 , 29/30, 48/49, 74/75, 165/ 166, 202/203 , 220/221 , 246/247, 251 /252, 269/270, 270/271 , 304/305, 305/306, 357/358, 430/431 , 443/444, 454/455, 455/456, 463/464, 465/466, 476/477, 507/508 and/or 509/510 in hEGFr, or a peptide bond in proximity to these positions in hEGFr, or peptide bonds in protein targets related to hEGFr at positions having structural homology or sequence hom ology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Epithelial cell adhesion molecule (hEp-CAM) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatm ent of diseases, such as, but not lim ited to, colorectal cancer, as well as other diseases connected with hEp-CAM.
  • said enzyme or said fusion protein is capable of specifically inactivating hEp-CAM (SEQ I D NO: 125) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 14/ 15, 19/20, 25/26, 30/31 , 33/34, 55/56 an/or 70/71 (m ost preferred between positions 14/ 15, 30/31 and/or 70/71 ) in hEp-CAM, or a peptide bond in proxim ity to these positions in hEp-CAM, or peptide bonds in protein targets related to hEp-CAM at positions having structural homology or sequence hom ology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human I nsulin- like growth factor I receptor (hi GF-1 r) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, a variety of cancers including breast cancer, as well as other diseases connected with hl GF- 1 r.
  • said enzyme or said fusion protein is capable of specifically inactivating hl GF-1 r (SEQ I D NO: 126) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 59/60, 1 15/ 1 1 6, 146/ 147, 171 / 172, 191 / 1 92, 290/291 , 306/307, 307/308, 335/336, 336/337, 455/456 and/or 470/471 (m ost preferred between positions 306/307, 307/308, 335/336 and/or 470/471 ) in hl GF- 1 r, or a peptide bond in proxim ity to these positions in hl GF-1 r, or peptide bonds in protein targets related to h l GF-1 r at positions having structural hom ology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human T-cell surface antigen CD2 precursor (hCD2).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, psoriasis, as well as other diseases connected with hCD2.
  • said enzyme or said fusion protein is capable of specifically inactivating hCD2 (SEQ ID NO: 128).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 42/43, 43/44, 48/49, 49/50, 51/52, 54/55, 63/64, 69/70, 89/90 and/or 91/92 (most preferred between positions 43/44, 51/52 and/or 89/90) in hCD2, or a peptide bond in proximity to these positions in hCD2, or peptide bonds in protein targets related to hCD2 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human T-cell surface glycoprotein CD4 (hCD4).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, psoriasis, transplant rejection, graft-versus-host colitis, autoimmune disorders and rheumatoid arthritis, as well as other diseases connected with hCD4.
  • said enzyme or said fusion protein is capable of specifically inactivating hCD4 (SEQ ID NO: 129).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 166/167, 167/168, 206/207, 219/220, 224/225, 226/227, 251/252, 252/253, 322/323, 329/330 and/or 334/335 (most preferred between positions 206/207, 219/220, 251/252 and/or 252/253) in hCD4, or a peptide bond in proximity to these positions in hCD4, or peptide bonds in protein targets related to hCD4 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human lntegrin alpha-L (hCD11a).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, psoriasis as well as other diseases connected with hCD11a.
  • said enzyme or said fusion protein is capable of specifically inactivating hCD11a (SEQ ID NO: 130).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 145/146, 152/153, 156/157, 159/160, 160/161, 177/178, 178/179, 189/190, 190/191, 191/192, 193/194, 197/198, 200/201, 221/222, 229/230, 249/250, 253/254, 268/269, 290/291, 297/298, 304/305 and/or 305/306 (most preferred between positions 145/146, 159/160, 160/161, 189/190, 229/230, 249/250, 268/269, 297/298, 304/305 and/or 305/306) in hCD11a, or a peptide bond in proximity to these positions in hCD11 a, or peptide bonds in protein targets related to hCD11 a at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Interferon-gamma receptor alpha chain (hlFN- gamma-R1).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, classical Hodgkin's Lymphoma (cHL) and type I diabetes, as well as other diseases connected with hlFN-gamma-R1.
  • said enzyme or said fusion protein is capable of specifically inactivating hlFN-gamma-R1 (SEQ ID NO:136).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 49/50, 52/53, 62/63, 106/107, 122/123, 174/175, 215/216 and/or 222/223 (most preferred between positions 49/50, 122/123, 174/175 and/or 215/216) in hlFN-gamma-R1 , or a peptide bond in proximity to these positions in hlFN-gamma-R1 , or peptide bonds in protein targets related to hlFN-gamma-R1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Platelet membrane glycoprotein llb/llla (hGPIIb/ll Ia).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, unstable angina, carotid stenting, ischemic stroke, peripheral vascular diseases, angiogenesis-related diseases and disseminating tumors, as well as other diseases connected with hGPIIb/ll Ia.
  • said enzyme or said fusion protein is capable of specifically inactivating hGPIIb/llla (SEQ ID NO:141).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 67/68, 91/92, 129/130, 143/144, 144/145, 181/182, 208/209, 209/210, 216/217, 239/240, 261/262, 410/411, 532/533, 556/557, 557/558, 597/598, 650/651 and/or 689/690 (most preferred between positions 67/68, 261/262, 410/411, 650/651 and/or 689/690) in hGPIIb/llla, or a peptide bond in proximity to these positions in hGPIIb/llla, or peptide bonds in protein targets related to hGPIIb/llla at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Intercellular adhesion molecule-1 (hlCAM-1).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, Crohn's disease, as well as other diseases connected with hlCAM-1.
  • said enzyme or said fusion protein is capable of specifically inactivating hlCAM-1 (SEQ ID NO:142).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 40/41, 88/89, 97/98, 102/103, 128/129, 131/132, 132/133, 149/150, 150/151, 160/161 and/or 166/167 (most preferred between positions 88/89, 102/103, 150/151, 160/161 and/or 166/167) in hlCAM-1, or a peptide bond in proximity to these positions in hlCAM-1, or peptide bonds in protein targets related to hlCAM-1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human TGF-beta receptor type Il (hTGF-beta RII).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, diffuse systemic sclerosis, as well as other diseases connected with hTGF-beta RII.
  • said enzyme or said fusion protein is capable of specifically inactivating hTGF-beta RII (SEQ ID NO: 145).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 32/33, 34/35, 35/36, 66/67, 67/68, 69/70, 82/83, 103/104, 104/105, 105/106, 118/119, 122/123 and/or 130/131 (most preferred between positions 32/33, 34/35, 66/67, 69/70, 104/105, 122/123 and/or 130/131) in hTGF-beta RII, or a peptide bond in proximity to these positions in hTGF-beta RII, or peptide bonds in protein targets related to hTGF-beta RII at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Membrane cofactor protein (hMCP).
  • hMCP human Membrane cofactor protein
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, renal tumors, uveal melanomas and gastrointestinal tumors, as well as other diseases connected with hMCP.
  • said enzyme or said fusion protein is capable of specifically inactivating hMCP (SEQ ID NO: 146).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 15/16, 17/18, 25/26, 31/32, 32/33, 35/36, 48/49, 67/68, 69/70, 110/111, 119/120 and/or 125/126 (most preferred between positions 1 5/ 16, 32/33, 48/49, 1 19/ 120 and/or 125/ 126) 130/ 131 ) in hMCP, or a peptide bond in proxim ity to these positions in hMCP, or peptide bonds in protein targets related to hMCP at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Protease activated receptor 1 (hPAR1 ) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, thrombosis, as well as other diseases connected with hPAFM .
  • said enzyme or said fusion protein is capable of specifically inactivating hPAR1 (SEQ I D NO: 1 10) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 46/47, 51 /52 and/or 52/53 in PAR1 , or a peptide bond in proxim ity to these positions in hPAR1 , or peptide bonds in protein targets related to hPAR1 at positions having structural hom ology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human Protease activated receptor 2 (hPAR2) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, Crohn's disease, Ulcerative colitis and I nflam matory bowel disease, asthma, inflam mation associated pain and arthritis, as well as other diseases connected with hPAR2.
  • said enzyme or said fusion protein is capable of specifically inactivating hPAR2 (SEQ I D NO: 1 1 1 ) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 41 /42, 51 /52 and/or 59/60 in hPAR2, or a peptide bond in proxim ity to these positions in hPAR2, or peptide bonds in protein targets related to hPAR2 at positions having structural homology or sequence homology to these positions.
  • the enzym e is a protease and is capable of hydrolysing human Protease activated receptor 4 (hPAR4) .
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not lim ited to, thrombosis, as well as other diseases connected with hPAR4.
  • said enzyme or said fusion protein is capable of specifically inactivating hPAR4 (SEQ I D NO: 1 13) .
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 68/69, 74/75 and/or 78/79 in hPAR4, or a peptide bond in proxim ity to these positions in hPAR4, or peptide bonds in protein targets related to hPAR4 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human 5-hydroxytryptamine 1A receptor (h5-HT-1A).
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, irritable bowel syndrome, as well as other diseases connected with h5-HT-1A.
  • said enzyme or said fusion protein is capable of specifically inactivating h5-HT-1A (SEQ ID NO: 117).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 101/102, 102/103, 181/182 and/or 370/371 in h5-HT-1A a peptide bond in proximity to these positions in h5-HT-1A, or peptide bonds in protein targets related to h5-HT-1A at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolysing human carcinoembryonic antigen (hCEA).
  • hCEA human carcinoembryonic antigen
  • the enzymes or the fusion protein can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, colon cancer, as well as other diseases connected with hCEA.
  • said enzyme or said fusion protein is capable of specifically inactivating hCEA (SEQ ID NO: 138).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 17/18, 69/70, 71/72, 74/75, 77/78, 98/99, 116/117, 126/127 and/or 128/129 in hCEA, or a peptide bond in proximity to these positions in hCEA, or peptide bonds in protein targets related to hCEA at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human interleukin-1 receptor type 1 (hi L- 1 R) .
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, asthma, inflammation, rheumatic disorders, as well as other diseases connected with hi L- 1 R.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-1R(SEQ ID NO: 150).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 35/36, 42/43, 43/44, 44/45, 46/47, 56/57, 61/62, 72/73, 82/83, 98/99, 132/133, 137/138, 140/141, 145/146, 146/147, 148/149, 153/154, 171/172, 172/173, 190/191, 202/203, 203/204, 205/206, 242/243, 245/246, 251/252, 252/253, 253/254, 254/255, 261/262, 262/263, 265/266, 271/272, 272/273, 283/284, 285/286, 287/288, 290/291 and/or 298/299 (most preferred between positions 44/45, 46/47, 52/53, 61/62, 137/138, 148/149, 153/154, 171/172, 172/173, 203/204, 252/253, 253/254, 26
  • the enzyme is a protease and is capable of hydrolyzing human interleukin-2 receptor beta chain (hlL-2Rb).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, acute myeloid leukemia, inflammation, psoriasis, as well as other diseases connected with hlL-2Rb.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-2Rb (SEQ ID NO: 151).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 38/39, 40/41, 41/42, 42/43, 43/44, 49/50, 71/72, 76/77, 81/82, 85/86, 86/87, 89/90, 91/92, 102/103, 105/106, 118/119, 134/135, 152/153, 153/154, 154/155, 161/162, 163/164, 165/166, 175/176, 194/195 and/or 197/198 (most preferred between positions 38/39, 43/44, 81/82, 118/119, 134/135, 153/154, 161/162, 165/166 and/or 194/195) in hlL-2Rb or a peptide bond in proximity to these positions in hlL-2Rb, or peptide bonds in protein targets related to hlL-2Rb at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human interleukin-4 receptor alpha chain (hlL-4Ra).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, asthma and allergy, as well as other diseases connected with hlL-4Ra.
  • said enzyme or said fusion protein is capable of specifically inactivating hlL-4Ra (SEQ ID NO: 152).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 22/23, 32/33, 45/46, 52/53, 66/67, 67/68, 87/88, 112/113, 125/126, 127/128, 129/130, 141/142, 143/144, 148/149, 150/151, 154/155, 156/157, 160/161, 167/168, 173/174, 175/176, 177/178, 183/184 and/or 189/190 (most preferred between positions 52/53, 66/67, 112/113, 125/126, 143/144, 154/155 and/or 160/161) in hlL-4Ra or a peptide bond in proximity to these positions in hlL-4Ra, or peptide bonds in protein targets related to hlL-4Ra at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human tumor necrosis factor receptor (hTNFR).
  • hTNFR human tumor necrosis factor receptor
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, asthma, Crohn ' s disease, HIV infection, inflammation, psoriasis, rheumatoid arthritis, as well as other diseases connected with hTNFR.
  • said enzyme or said fusion protein is capable of specifically inactivating hTNFR (SEQ ID NO: 153).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 40/41, 49/50, 51/52, 53/54, 54/55, 56/57, 68/69, 75/76, 77/78, 78/79, 79/80, 84/85, 91/92, 99/100, 100/101, 107/108, 109/110, 131/132, 132/133, 147/148, 149/150, 157/158, 158/159 and/or 161/162 (most preferred between positions 40/41, 49/50, 54/55, 78/79, 84/85, 99/100, 107/108, 109/110, 132/133, 149/150 and/or 157/158) in hTNFR or a peptide bond in proximity to these positions in hTNFR, or peptide bonds in protein targets related to hTNFR at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human C-X-C chemokine receptor type 5 (hCCR5).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, HIV infection, as well as other diseases connected with hCCR5.
  • said enzyme or said fusion protein is capable of specifically inactivating hCCR5 (SEQ ID NO: 154).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 10/11, 12/13, 16/17, 19/20, 22/23, 23/24, 25/26, 27/28, 29/30, 34/35, 42/43, 50/51, 110/111, 115/116, 120/121, 123/124, 189/190, 201/202, 204/205, 207/208, 211/212, 215/216, 216/217, 219/220, 281/282, 285/286, 287/288, 290/291 and/or 294/295 in hCCR5 or a peptide bond in proximity to these positions in hCCR5, or peptide bonds in protein targets related to hCCR5 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human C-X-C chemokine receptor type 3 (hCXCR3).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, multiple sclerosis, rheumatoid arthritis, as well as other diseases connected with hCXCR3.
  • said enzyme or said fusion protein is capable of specifically inactivating hCXCR3 (SEQ ID NO: 155).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 4/5, 7/8, 13/14, 21/22, 23/24, 27/28, 28/29, 29/30, 35/36, 46/47, 47/48, 52/53, 53/54, 112/113, 117/118, 119/120, 125/126, 195/196, 197/198, 205/206, 207/208, 212/213, 278/279, 282/283, 288/289, 292/293, 293/294, 295/296 and/or 297/298 in hCXCR3 or a peptide bond in proximity to these positions in hCXCR3, or peptide bonds in protein targets related to hCXCR3 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human epidermal growth factor (hEGF).
  • hEGF human epidermal growth factor
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, carcinomas, solid cancers like breast, colon or stomach cancer, as well as other diseases connected with hEGF.
  • said enzyme or said fusion protein is capable of specifically inactivating hEGF (SEQ ID NO: 156).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 11/12, 13/14, 17/18, 22/23, 27/28, 28/29, 40/41 , 41/42, 44/45, 45/46, 46/47, 49/50 and/or 50/51 (most preferred between positions 11/12, 17/18, 44/45 an/or 49/50) in hEGF or a peptide bond in proximity to these positions in hEGF, or peptide bonds in protein targets related to hEGF at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human fibroblast growth factor (hFGF-1).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, angiogenesis, as well as other diseases connected with hFGF-1.
  • said enzyme or said fusion protein is capable of specifically inactivating hFGF-1 (SEQ ID NO: 157).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 28/29, 35/36, 36/37, 37/38, 39/40, 49/50, 60/61, 70/71, 74/75, 81/82, 94/95, 100/101, 101/102, 104/105, 105/106, 112/113, 113/114, 119/120, 122/123, 125/126 and/or 128/129 (most preferred between positions 28/29, 35/36, 70/71, 81/82, 100/101, 104/105, 113/114 adnd/or 122/123) in hFGF-1 or a peptide bond in proximity to these positions in hFGF-1, or peptide bonds in protein targets related to hFGF-1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human fibroblast growth factor receptor 1 (hFGFR-1).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, angiogenesis, as well as other diseases connected with hFGFR-1.
  • said enzyme or said fusion protein is capable of specifically inactivating hFGFR-1 (SEQ ID NO: 158).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 15/16, 19/20, 22/23, 23/24, 24/25, 32/33, 49/50, 55/56, 56/57, 58/59, 60/61, 69/70, 70/71, 93/94, 95/96, 96/97, 110/111, 114/115, 134/135, 181/182, 182/183, 189/190, 194/195, 195/196 and/or 215/216 (most preferred between positions 19/20, 24/25, 49/50, 55/56, 58/59, 60/61, 95/96, 96/97, 110/111, 181/182, 189/190, 195/196 and/or 215/216) in hFGFR-1 or a peptide bond in proximity to these positions in hFGFR-1 , or peptide bonds in protein targets related to hFGFR-1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human fibroblast growth factor receptor 2 (hFGFR-2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancers like astrocytomas, as well as other diseases connected with hFGFR-2.
  • said enzyme or said fusion protein is capable of specifically inactivating hFGFR-2 (SEQ ID NO: 159).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 9/10, 10/11, 14/15, 17/18, 18/19, 19/20, 32/33, 44/45, 50/51, 51/52, 53/54, 55/56, 62/63, 90/91, 91/92, 104/105, 105/106, 109/110, 127/128, 135/136, 149/150, 150/151, 175/176, 176/177, 177/178, 182/183, 189/190, 190/191 and/or 210/211 (most preferred between positions 14/15, 19/20, 53/54, 55/56, 91/92, 105/106, 149/150, 150/151, 175/176, 176/177, 182/183, 189/190 and/or 210/211) in hFGFR-2 or a peptide bond in proximity to these positions in hFGFR-2, or peptide bonds in protein targets related to hFGFR-2 at positions having structural homo
  • the enzyme is a protease and is capable of hydrolyzing human C-C chemokine receptor type 1 (hCCR1).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, multiple sclerosis, as well as other diseases connected with hCCR1.
  • said enzyme or said fusion protein is capable of specifically inactivating hCCR1 (SEQ ID NO: 160).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 2/3, 8/9, 9/10, 10/11, 11/12, 15/16, 17/18, 18/19, 26/27, 29/30, 30/31, 32/33, 92/93, 93/94, 94/95, 96/97, 97/98, 98/99, 99/100, 101/102, 103/104, 107/108, 173/174, 176/177, 177/178, 178/179, 187/188, 190/191, 193/194, 194/195, 195/196, 196/197, 266/267, 272/273, 274/275, 277/278 and/or 280/281 in hCCR1 or a peptide bond in proximity to these positions in hCCR1, or peptide bonds in protein targets related to hCCFM at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human C-C chemokine receptor type 2 (hCCR2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, multiple sclerosis, rheumatoid arthritis, as well as other diseases connected with hCCR2.
  • said enzyme or said fusion protein is capable of specifically inactivating hCCR2 (SEQ ID NO: 161).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 6/7, 8/9, 9/10, 11/12, 15/16, 18/19, 19/20, 23/24, 25/26, 27/28, 34/35, 36/37, 38/39, 105/106, 106/107, 108/109, 114/115, 180/181, 183/184, 184/185, 185/186, 188/189, 193/194, 194/195, 196/197, 198/199, 201/202, 206/207, 270/271, 271/272, 272/273, 278/279 and/or 284/285 in hCCR2 or a peptide bond in proximity to these positions in hCCR2, or peptide bonds in protein targets related to hCCR2 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human tyrosine protein kinase (hSrc).
  • hSrc human tyrosine protein kinase
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, osteoporosis, as well as other diseases connected with hSrc.
  • said enzyme or said fusion protein is capable of specifically inactivating hSrc (SEQ ID NO: 162).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 15/16, 22/23, 25/26, 59/60, 65/66, 87/88, 94/95, 99/100, 102/103, 123/124, 124/125, 126/127, 135/136, 147/148, 150/151, 153/154, 158/159, 176/177, 178/179, 182/183, 200/201, 216/217, 223/224, 234/235, 249/250, 261/262, 266/267, 271/272, 275/276, 277/278, 297/298, 327/328, 331/332, 333/334, 337/338, 354/355, 356/357, 378/379, 387/388, 397/398, 391/392, 395/396, 398/399, 407/408, 411/412, 418/419, 419/420, 420/421, 422/423, 423/424
  • the enzyme is a protease and is capable of hydrolyzing human RAC-beta serine/threonine protein kinase (hAkt-2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, as well as other diseases connected with hAkt-2.
  • said enzyme or said fusion protein is capable of specifically inactivating hAkt-2 (SEQ ID NO: 163).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 9/10, 15/16, 25/26, 26/27, 27/28, 39/40, 63/64, 71/72, 72/73, 78/79, 79/80, 98/99, 99/100, 100/101, 104/105, 105/106, 106/107, 120/121, 124/125, 125/126, 141/142, 170/171, 178/179, 179/180, 181/182, 182/183, 184/185, 206/207, 209/210, 211/212, 212/213, 220/221, 221/222, 223/224, 226/227, 242/243, 243/244, 245/246, 256/257, 260/261, 262/263, 275/276, 276/277, 282/283, and /or 292/293 (most preferred between positions 27/28, 39/40, 41/42, 72/73, 78/79,
  • the enzyme is a protease and is capable of hydrolyzing human substance P (substance P).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancers like small cell lung cancer, colorectal cancer, astrocytic/glial brain tumors, as well as other diseases connected with substance P.
  • said enzyme or said fusion protein is capable of specifically inactivating substance P (SEQ ID NO: 164).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1/2, 3/4, 7/8 and/or 8/9 in substance P or a peptide bond in proximity to these positions in substance P, or peptide bonds in protein targets related to substance P at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human Bradykinin (Bradykinin).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, vascular and neuro-glial pathology in diabetic retinopathy, cerebral ischemia and trauma, hyperalgesia, inflammatory diseases or conditions, asthma and cancer, pain, pathological vascular leakage or vasodilation, pathological contraction of various smooth muscles, pathological cell proliferation, as well as other diseases connected with Bradykinin.
  • said enzyme or said fusion protein is capable of specifically inactivating Bradykinin (SEQ ID NO: 165).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1/2, 5/6 and/or 8/9 in Bradykinin or a peptide bond in proximity to these positions in Bradykinin, or peptide bonds in protein targets related to Bradykinin at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human Coagulation factor IX (Factor IX).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, hamophilia B, as well as other diseases connected with Factor IX.
  • said enzyme or said fusion protein is capable of specifically inactivating Factor IX (SEQ ID NO: 166).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 21/22, 23/24, 36/37, 38/39, 59/60, 63/64, 74/75, 75/76, 87/88, 111/112, 112/113, 119/120, 127/128, 128/129, 129/130, 130/131, 136/137, 137/138, 149/150,151/152, 153/154, 162/163, 167/168, 173/174, 176/177, 190/191, 209/210, 222/223, 223/224 and/or 227/228 (most preferred between positions 63/64, 127/128, 136/137, 149/150, 151/152, 173/174, 176/177 and/or 227/228) in Factor IX or a peptide bond in proximity to these positions in Factor IX, or peptide bonds in protein targets related to Factor IX at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human glycogen synthase kinase-3-beta (hGSK-3).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, diabetes, as well as other diseases connected with hGSK-3.
  • said enzyme or said fusion protein is capable of specifically inactivating hGSK-3 (SEQ ID NO: 167).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 16/17, 19/20, 24/25, 26/27, 43/44, 52/53, 57/58, 60/61, 62/63, 68/69, 69/70, 87/88, 88/89, 89/90, 90/91, 91/92, 107/108, 110/111, 112/113, 114/115, 116/117, 156/157, 158/159, 175/176, 177/178, 182/183, 186/187, 187/188, 189/190, 226/227, 230/231, 234/235, 244/245, 245/246, 248/249, 249/250, 254/255, 256/257, 263/264, 269/270, 272/273, 274/275, 307/308, 308/309, 311/312, 315/316 and/or 321/322 (most preferred between positions 57/58,
  • the enzyme is a protease and is capable of hydrolyzing human cyclin-dependent protein kinase-2 (hcdk-2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, as well as other diseases connected with hcdk-2.
  • said enzyme or said fusion protein is capable of specifically inactivating hcdk-2 (SEQ ID NO: 168).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 9/10, 12/13, 15/16, 19/20, 22/23, 24/25, 34/35, 50/51, 57/58, 68/69, 73/74, 75/76, 88/89, 89/90, 92/93, 122/123, 138/139, 162/163, 178/179, 179/180, 180/181, 199/200, 200/201, 206/207, 208/209, 210/211, 217/218, 223/224, 224/225, 237/238, 242/243, 245/246, 247/248, 250/251 , 273/274 and/or 291/292 (most preferred between positions 12/13, 50/51, 57/58, 73/74, 138/139, 180/181, 200/201, 206/207, 223/224, 242/243, 247/248 and/or 273/274) in hcdk-2 or
  • the enzyme is a protease and is capable of hydrolyzing human caspase-2 (caspase-2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, pathological ischemic cell death, pathological reperfusion cell death, pathological retinal neuronal cell death, pathological apoptosis initiated by beta-amyloid toxicity or by trophic factor deprivation, diseases with mitochondrial permeabilization components, toxin cell death induced by cytolethal distending toxin (CDT), acute ischemic injury, infertility, wounds, as well as other diseases connected with caspase-2.
  • diseases such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neuro
  • said enzyme or said fusion protein is capable of specifically inactivating caspase-2 (SEQ ID NO: 169). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 13/14, 14/15, 24/25, 28/29, 44/45, 45/46, 46/47, 48/49, 54/55, 65/66, 70/71, 81/82, 84/85, 96/97, 118/119, 120/121, 126/127, 154/155, 155/156, 186/187, 188/189, 212/213, 213/214, 227/228, 228/229, 247/248, 249/250, 251/252, 259/260 and/or 272/273 (most preferred between positions 48/49, 81/82, 154/155, 186/187, 213/214, 228/229 and/or 251/252) in caspase-2 or a peptide bond in proximity to these positions in caspase-2, or peptid
  • the enzyme is a protease and is capable of hydrolyzing human caspase-3 (caspase-3).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, neural degeneration in amyotrophic lateral sclerosis, Huntington, Infection with vesicular stomatitis virus (VSV), as well as other diseases connected with caspase-3.
  • diseases such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, neural de
  • said enzyme or said fusion protein is capable of specifically inactivating caspase-3 (SEQ ID NO: 170). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 12/13, 25/26, 29/30, 40/41, 47/48, 48/49, 51/52, 54/55, 56/57, 58/59, 66/67, 67/68, 73/74, 74/75, 77/78, 78/79, 79/80, 82/83, 83/84, 110/111, 139/140, 151/152, 152/153, 153/154, 158/159, 196/197, 198/199, 200/201, 201/202, 218/219, 220/221, 225/226 and/or 248/249 (most preferred between positions 29/30, 40/41, 51/52, 56/57, 67/68, 73/74, 79/80, 83/84, 153/154, 218/219 and
  • the enzyme is a protease and is capable of hydrolyzing human caspase-7 (caspase-7).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, toxin cell death induced by cytolethal distending toxin (CDT), acute lymphoblast leukemia, as well as other diseases connected with caspase-7.
  • diseases such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, toxin cell death induced by
  • said enzyme or said fusion protein is capable of specifically inactivating caspase-7 (SEQ ID NO: 171). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 35/36, 42/43, 43/44, 56/57, 57/58, 68/69, 72/73, 76/77, 79/80, 84/85, 88/89, 101/102, 102/103, 105/106, 106/107, 107/108, 149/150, 188/189, 189/190, 227/228, 228/229, 231/232, 232/233, 251/252, 255/256, 256/257 and/or 277/278 (most preferred between positions 57/58, 79/80, 84/85, 102/103, 107/108, 228/229, 231/232, 232/233 and/or 255/256) in caspase-7 or a peptide bond in proximity to these positions in caspase-7, or
  • the enzyme is a protease and is capable of hydrolyzing human caspase-9 (caspase-9).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, neurological diseases like stroke, neurodegenerative diseases, brain injury caused by hypoxia, Parkinson's, amyotrophic lateral sclerosis (ALS), as well as other diseases connected with caspase-9.
  • diseases such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, neurological diseases like stroke,
  • said enzyme or said fusion protein is capable of specifically inactivating caspase-9 (SEQ ID NO: 172). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 4/5, 19/20, 34/35, 35/36, 39/40, 49/50, 52/53, 53/54, 54/55, 63/64, 67/68, 71/72, 72/73, 79/80, 84/85, 112/113, 123/124, 151/152, 158/159, 215/216, 216/217, 217/218, 219/220, 223/224, 226/227, 229/230, 230/231, 233/234, 235/236 and/or 258/259 (most preferred between positions 19/20, 35/36, 34/35, 52/53, 53/54, 71/72, 79/80, 219/220 and/or 230/231) in caspase-9 or a peptide bond in proximity to these positions in caspase-9 or
  • the enzyme is a protease and is capable of hydrolyzing human apoptotic protease activating factor 1 (hApaf-1).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, as well as other diseases connected with hApaf-1.
  • diseases such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, as well as other diseases connected with hApaf-1.
  • diseases such as, but not limited to
  • said enzyme or said fusion protein is capable of specifically inactivating hApaf-1 (SEQ ID NO: 173). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 6/7, 13/14, 14/15, 17/18, 18/19, 19/20, 24/25, 27/28, 32/33, 39/40, 40/41, 41/42, 44/45, 46/47, 62/63, 63/64, 64/65, 66/67, 80/81, 81/82 and/or 82/83 (most preferred between positions 13/14, 14/15, 18/19, 41/42, 62/63 and/or 64/65) in hApaf-1 or a peptide bond in proximity to these positions in hApaf-1, or peptide bonds in protein targets related to hApaf-1 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human BH3 interacting domain death agonist (hBID).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, as well as other diseases connected with hBID.
  • said enzyme or said fusion protein is capable of specifically inactivating hBID (SEQ ID NO: 174).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 6/7, 15/16, 32/33, 36/37, 37/38, 38/39, 53/54, 54/55, 56/57, 57/58, 58/59, 62/63, 65/66, 73/74, 77/78, 79/80, 101/102, 116/117, 120/121, 122/123, 123/124, 124/125, 134/135, 140/141, 142/143, 143/144, 145/146 and/or 170/171 (most preferred between positions 36/37, 53/54, 57/58, 62/63, 65/66, 73/74 and/or 79/80) in hBID or a peptide bond in proximity to these positions in hBID, or peptide bonds in protein targets related to hBID at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human poly (ADP-ribose) polymerase- 1 (hPARP).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, degenerative disorders like neurodegenerative diseases, ischemic acell death, reperfusion cell death, acute ischemic injury, infertility, wounds, as well as other diseases connected with hPARP.
  • said enzyme or said fusion protein is capable of specifically inactivating hPARP (SEQ ID NO: 175).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 13/14, 19/20, 22/23, 23/24, 27/28, 29/30, 34/35, 39/40, 42/43, 43/44, 65/66, 70/71, 74/75, 82/83, 86/87, 87/88, 114/115, 118/119, 122/123, 126/127, 133/134, 134/135, 141/142, 144/145, 145/146, 146/147, 148/149, 149/150, 158/159, 179/180, 181/182, 188/189, 196/197, 222/223, 270/271, 272/273, 282/283, 304/305, 307/308 and/or 320/321 (most preferred between positions 22/23, 43/44, 118/119, 122/123, 145/146, 146/147, 148/149, 179/180 and/or 272/273) in
  • the enzyme is a protease and is capable of hydrolyzing human Tumor protein p53 (hp53).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, apoptosis associated disorders like immunodeficiency diseases (AIDS/HIV), Alzheimers, senescence, any degenerative disorders (neurodegenerative diseases), ischemic and reperfusion cell death, acute ischemic injury, infertility, wounds, as well as other diseases connected with hp53.
  • said enzyme or said fusion protein is capable of specifically inactivating hp53 (SEQ ID NO: 176).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 10/11, 14/15, 17/18, 27/28, 33/34, 53/54, 55/56, 63/64, 78/79, 81/82, 87/88, 88/89, 93/94, 105/106, 109/110, 112/113, 114/115, 115/116, 116/117, 131/132, 135/136, 155/156, 156/157, 166/167, 180/181, 187/188, 189/190, 190/191, 192/193, 193/194 and/or 194/195 (most preferred between positions 14/15, 27/28, 53/54, 88/89, 114/115, 116/117, 131/132, 155/156, 190/191 and/or 194/195) in hp53 or a peptide bond in proximity to these positions in hp53, or peptide bonds in protein targets related to hp53 or
  • the enzyme is a protease and is capable of hydrolyzing human Rselectin (hP-selectin).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammation, as well as other diseases connected with hP-selectin.
  • said enzyme or said fusion protein is capable of specifically inactivating hP-selectin (SEQ ID NO: 177).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 16/17, 17/18, 18/19, 22/23, 23/24, 36/37, 37/38, 40/41, 44/45, 45/46, 54/55, 55/56, 66/67, 67/68, 72/73, 74/75, 78/79, 80/81, 84/85, 85/86, 88/89, 92/93, 94/95, 96/97, 106/107, 107/108, 111/112, 112/113, 124/125, 129/130, 140/141, 152/153 and/or 154/155 (most preferred between positions 17/18, 22/23, 44/45, 55/56, 72/73, 78/79, 84/85, 85/86, 107/108, 112/113, 152/153 and/or 154/155) in hP-selectin or a peptide bond in proximity to these positions in hP-s
  • the enzyme is a protease and is capable of hydrolyzing human Oncostatin M (hOSM).
  • hOSM human Oncostatin M
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer like prostate cancer, as well as other diseases connected with hOSM.
  • said enzyme or said fusion protein is capable of specifically inactivating hOSM (SEQ ID NO: 178).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 11/12, 19/20, 22/23, 26/27, 32/33, 36/37, 41/42, 44/45, 46/47, 47/48, 50/51, 52/53, 59/60, 60/61, 67/68, 68/69, 84/85, 97/98, 99/100, 100/101, 106/107, 107/108, 109/110, 122/123, 126/127, 133/134, 158/159, 162/163, 163/164 and/or 175/176 (most preferred between positions 19/20, 44/45, 47/48, 60/61, 67/68, 97/98, 100/101, 109/110, 126/127, 133/134, 162/163 and/or 175/176) in hOSM or a peptide bond in proximity to these positions in hOSM, or peptide bonds in protein targets related to hOSM at positions having structural homology
  • the enzyme is a protease and is capable of hydrolyzing human cathepsin B (cathepsin B).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammatory bowel disease, Crohn ' s disease, colitis ulcerosa, as well as other diseases connected with cathepsin B.
  • said enzyme or said fusion protein is capable of specifically inactivating cathepsin B (SEQ ID NO: 179).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 9/10, 18/19, 53/54, 69/70, 75/76, 78/79, 85/86, 86/87, 94/95, 95/96, 124/125, 127/128, 130/131, 141/142, 146/147, 148/149, 151/152, 158/159, 159/160, 165/166, 166/167, 184/185, 194/195, 224/225, 227/228, 238/239, 245/246 and/or 252/253 (most preferred between positions 75/76, 85/86, 95/96, 124/125, 130/131, 141/142, 148/149, 158/159 and/or 194/195) in cathepsin B or a peptide bond in proximity to these positions in cathepsin B, or peptide bonds in protein targets related to cathepsin B at positions having structural homology or sequence homo
  • the enzyme is a protease and is capable of hydrolyzing human cathepsin D (cathepsin D).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammatory bowel disease, Crohn ' s disease, colitis ulcerosa, as well as other diseases connected with cathepsin D.
  • said enzyme or said fusion protein is capable of specifically inactivating cathepsin D (SEQ ID NO: 180).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 10/11, 18/19, 47/48, 54/55, 58/59, 62/63, 63/64, 67/68, 69/70, 75/76, 86/87, 111/112, 112/113, 141/142, 158/159, 161/162, 172/173, 174/175, 189/190, 191/192, 192/193, 197/198, 202/203, 203/204, 214/215, 223/224, 224/225, 227/228, 242/243, 243/244, 245/246, 246/247, 249/250, 266/267, 281/282, 283/284, 284/285, 288/289, 289/290, 293/294, 299/300, 310/311 and/or 336/337 (most preferred between positions 54/55, 62/63, 63/64, 112/113, 158/159, 174/175, 189
  • the enzyme is a protease and is capable of hydrolyzing human cathepsin L (cathepsin L).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammatory bowel disease, Crohn ' s disease, colitis ulcerosa, as well as other diseases connected with cathepsin L.
  • said enzyme or said fusion protein is capable of specifically inactivating cathepsin L (SEQ ID NO: 181).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 9/10, 10/11, 40/41, 41/42, 44/45, 72/73, 76/77, 79/80, 86/87, 87/88, 95/96, 96/97, 99/100, 103/104, 104/105, 114/115, 117/118, 120/121, 124/125, 141/142, 148/149, 155/156, 159/160, 160/161, 182/183, 189/190, 193/194, 198/199, 191/192, 192/193, 205/206 and/or 206/207 (most preferred between positions 40/41, 87/88, 95/96, 103/104, 120/121, 141/142, 155/156, 159/160, 192/193 and/or 206/207) in cathepsin L or a peptide bond in proximity to these positions in cathepsin L, or peptide bonds in protein targets related to cathepsin
  • the enzyme is a protease and is capable of hydrolyzing human Galectin-3 (hGalectin-3).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammatory bowel dsease, Crohn ' s disease, colitis ulcerosa, as well as other diseases connected with hGalectin-3.
  • said enzyme or said fusion protein is capable of specifically inactivating hGalectin-3 (SEQ ID NO: 182).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 5/6, 16/17, 26/27, 31/32, 35/36, 52/53, 55/56, 56/57, 65/66, 68/69, 70/71, 71/72, 72/73, 73/74, 80/81, 83/84, 92/93, 97/98, 102/103, 111/112, 113/114, 114/115,126/127, 128/129 and/or 134/135 (most preferred between positions 55/56, 65/66, 70/71, 102/103, 113/114 and/or 128/129) in hGalectin-3or a peptide bond in proximity to these positions in hGalectin-3, or peptide bonds in protein targets related to hGalectin-3 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human receptor tyrosine-protein kinase erbB-2 (hHER2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, as well as other diseases connected with hHER2.
  • said enzyme or said fusion protein is capable of specifically inactivating hHER2 (SEQ ID NO: 183).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 18/19, 70/71, 87/88, 88/89, 99/100, 116/117, 135/136, 143/144, 153/154, 163/164, 168/169, 188/189, 206/207, 216/217, 226/227, 252/253, 255/256, 258/259, 264/265, 266/267, 279/280, 311/312, 314/315, 318/319, 326/327, 330/331, 332/333, 357/358, 360/361, 373/374, 395/396, 477/478, 479/480, 480/481, 481/482, 485/486, 495/496, 514/515, 520/521, 521/522, 523/524, 530/531, 532/533, 536/537, 558/559, 560/561, 568/569, 577/578, 592/5
  • the enzyme is a protease and is capable of hydrolyzing human matrix metalloproteinase-7 (hMMP-7).
  • hMMP-7 human matrix metalloproteinase-7
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, as well as other diseases connected with hMMP-7.
  • said enzyme or said fusion protein is capable of specifically inactivating hMMP-7 (SEQ ID NO: 184).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 13/14, 22/23, 24/25, 25/26, 33/34, 37/38, 44/45, 45/46, 51/52, 52/53, 55/56, 66/67, 73/74, 76/77, 100/101, 101/102, 102/103, 103/104, 106/107, 133/134, 146/147, 151/152, 155/156, 162/163 and/or 166/167 (most preferred between positions 24/25, 33/34, 51/52, 55/56, 73/74, 76/77, 101/102, 133/134 and/or 146/147) in hMMP-7 or a peptide bond in proximity to these positions in hMMP-7, or peptide bonds in protein targets related to hMMP-7 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human matrix metalloproteinase-14 (hMMP-14).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, as well as other diseases connected with hMMP-14.
  • said enzyme or said fusion protein is capable of specifically inactivating hMMP-14 (SEQ ID NO: 185).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 12/13, 20/21, 26/27, 27/28, 34/35, 35/36, 38/39, 47/48, 49/50, 57/58, 50/51, 53/54, 55/56, 58/59, 62/63, 72/73, 82/83, 84/85, 113/114, 115/116, 116/117, 141/142, 152/153, 154/155, 156/157, 165/166 and/or 166/167 (most preferred between positions 27/28, 38/39, 55/56, 57/58, 58/59, 82/83, 113/114, 116/117, 141/142 and/or 152/153) in hMMP-14 or a peptide bond in proximity to these positions in hMMP-14, or peptide bonds in protein targets related to hMMP-14 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human Vascular endothelial growth factor receptor 2 (hVEGFR-2).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, cancer, as well as other diseases connected with hVEGFR-2.
  • said enzyme or said fusion protein is capable of specifically inactivating hVEGFR-2 (SEQ ID NO: 186).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 13/14, 16/17, 19/20, 23/24, 33/34, 39/40, 53/54, 61/62, 88/89, 110/111, 112/113, 113/114, 115/116, 119/120, 120/121, 179/180, 184/185, 198/199, 203/204, 204/205, 208/209, 220/221, 245/246, 256/257, 260/261, 261/262, 291/292, 293/294, 294/295, 295/296, 298/299, 299/300, 301/302, 302/303, 307/308, 310/311, 311/312, 317/318, 322/323, 327/328, 336/337 and/or 339/340 (most preferred between positions 39/40, 53/54, 61/62, 88/89, 119/120, 120/121, 204/205, 260/261
  • the enzyme is a protease and is capable of hydrolyzing human Mitogen- activated protein kinase p38-alpha (hp38-kinase).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, intimal hyperplasia, vascular remodeling upon blood vessel injury, as well as other diseases connected with hp38-kinase.
  • said enzyme or said fusion protein is capable of specifically inactivating hp38-kinase (SEQ ID NO: 187).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 8/9, 11/12, 14/15, 21/22, 48/49, 53/54, 56/57, 66/67, 93/94, 96/97, 97/98, 117/118, 120/121, 123/124, 124/125, 159/160, 160/161, 162/163, 172/173, 175/176, 176/177, 177/178, 181/182, 199/200, 219/220, 229/230, 232/233, 236/237, 244/245, 247/248, 248/249, 252/253, 255/256, 257/258, 285/286, 286/287, 293/294, 294/295, 310/311, 312/313, 314/315, 315/316, 316/317, 320/321, 323/324, 329/330, 330/331 , 334/335, 335/336, 341/34
  • the enzyme is a protease and is capable of hydrolyzing human Stress- activated protein kinase JNK3 (hJNK3-kinase).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, intimal hyperplasia, vascular remodeling upon blood vessel injury, as well as other diseases connected with hJNK3-kinase.
  • said enzyme or said fusion protein is capable of specifically inactivating hJNK3-kinase (SEQ ID NO: 188).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 11/12, 19/20, 38/39, 43/44, 44/45, 53/54, 65/66, 72/73, 90/91, 93/94, 94/95, 106/107, 116/117, 118/119, 120/121, 124/125, 134/135, 179/180, 196/197, 197/198, 198/199, 214/215, 216/217, 222/223, 223/224, 233/234, 244/245, 245/246, 251/252, 253/254, 255/256, 259/260, 267/268, 271/272, 277/278, 279/280, 282/283, 302/303, 307/308, 308/309, 318/319, 319/320, 325/326, 338/339, 339/340, 344/345 and/or 345/346 (most preferred between positions 38/39, 90/91,
  • the enzyme is a protease and is capable of hydrolyzing human CX-C chemokine receptor type 4 (hCCR-4).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammation, as well as other diseases connected with hCCR-4.
  • said enzyme or said fusion protein is capable of specifically inactivating hCCR-4 (SEQ ID NO: 189).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 7/8, 10/11, 12/13, 14/15, 15/16, 20/21, 21/22, 22/23, 25/26, 26/27, 30/31, 31/32, 32/33, 36/37, 38/39, 102/103, 103/104, 104/105, 107/108, 110/111, 181/182, 182/183, 183/184, 184/185, 187/188, 188/189, 190/191, 193/194, 195/196, 262/263, 268/269, 271/272, 275/276, 277/278, 282/283 and/or 283/284 in hCCR-4 or a peptide bond in proximity to these positions in hCCR-4, or peptide bonds in protein targets related to hCCR-4 at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human beta-amyloid (hbeta-amyloid).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, Alzheimer, as well as other diseases connected with hbeta-amyloid.
  • said enzyme or said fusion protein is capable of specifically inactivating hbeta-amyloid (SEQ ID NO: 190).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 1/2, 3/4, 5/6, 7/8, 10/11, 11/12, 16/17, 19/20, 20/21, 22/23, 23/24 and/or 28/29 (most preferred between positions 7/8, 10/11, 11/12, 16/17 and/or 23/24) in hbeta-amyloid or a peptide bond in proximity to these positions in hbeta-amyloid, or peptide bonds in protein targets related to hbeta- amyloid at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing human Tumor necrosis factor receptor superfamily member 14 (hvemA).
  • hvemA Tumor necrosis factor receptor superfamily member 14
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, inflammatory bowel disease, Crohn ' s disease, colitis ulcerosa, as well as other diseases connected with hvemA.
  • said enzyme or said fusion protein is capable of specifically inactivating hvemA (SEQ ID NO: 191).
  • said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 14/15, 18/19, 23/24, 24/25, 26/27, 31/32, 54/55, 62/63, 68/69, 71/72, 75/76, 95/96, 101/102 and/or 103/104 (most preferred between positions 23/24, 26/27, 62/63, 68/69, 95/96, 101/102 and/or 103/104) in hvemA or a peptide bond in proximity to these positions in hvemA, or peptide bonds in protein targets related to hvemA at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing a TNF-superfamily member human B lymphocyte stimulator (hBlys).
  • the enzymes or the fusion proteins can thus be used for preparing medicaments for the treatment of diseases, such as, but not limited to, acute or chronic inflammatory diseases like rheumatoid arthritis, inflammatory bowel diseases, psoriasis, Crohn's disease, Ulcerative colitis, Sjogren's syndrome, systemic lupus erythematosus, multiple sclerosis, Systemic inflammatory response syndrome (SIRS), Graft-versus-host disease (GvhD) or sclerodermia, or for treatment of B-cell malignancies like classical Hodgkin's Lymphoma (cHL), mantle cell lymphoma, centrocytic lymphoma (CCL) or follicular lymphoma, as well as other diseases connected with hBlys.
  • diseases such as, but not limited to, acute
  • said enzyme or said fusion protein is capable of specifically inactivating hBlys (SEQ ID NO: 192). More preferably said enzyme or said fusion protein is capable of hydrolysing the peptide bonds between positions 160/161, 163/164, 173/174, 174/175, 181/182, 188/189, 192/193, 204/205, 206/207, 214/215, 215/216, 216/217, 222/223, 231/232, 252/253, 257/258, 265/266 and/or 273/274 (most preferred between positions 160/161, 163/164, 181/182, 188/189 and/or 222/223) in hBlys or a peptide bond in proximity to these positions in hBlys, or peptide bonds in protein targets related to hBlys at positions having structural homology or sequence homology to these positions.
  • the enzyme is a protease and is capable of hydrolyzing a target given in Table 1 a to treat a pathology or disease associated with that protein.
  • proximity to these positions refer to positions of peptide bonds that are between 10 and 5 Angstrom and/or 5 amino acids, preferably 3 amino acids, next to the positions of the peptide bonds.
  • the scaffold of the engineered enzyme provided in step (c) is of hum an origin in order to avoid or reduce im m unogenicity or allergenic effects associated with the application of the enzyme in the human body.
  • im m unogenicity and allergenicity can be reduced by deim m unization of the engineered enzyme.
  • Deim m unization in this context refers to the removal or exchange of those am ino acid residues that confer im m unogenicity or allergenicity to the engineered enzyme.
  • the target substrate is a pro-drug which is activated by the engineered enzyme.
  • the engineered enzyme has proteolytic activity and the target substrate is a protein target which is proteolytically activated. Exam ples of such pro-drugs are pro- proteins such as the inactivated forms of coagulations factors.
  • the engineered enzym e is an oxidoreductase and the target substrate is a chem ical that can be activated by oxidation.
  • the engineered enzym e is used for diagnostic puposes.
  • the engineered enzyme is target-specific protease.
  • Such diagnostic purposes com prise but are not lim ited to applications with the aim of diagnosing diseases, testing genetic predispositions or monitoring disease progression during therapy.
  • the diagnosis is based on the testing for the presence or absence of a disease-specific marker protein or a disease-specific variant of a human protein in test sam ples such as human tissue sam ples, blood sam ples or other sam ples taken from patients.
  • the testing em ploys a protease with specificity for a particular, disease- related target protein.
  • the testing is done by analysing the proteolytic degradation of such protein in the test sam ple.
  • the aim of the diagnostic test is to detect and/or quantify a disease-specific variant of a native human protein.
  • Such a diagnostic test em ploys a protease that is specific for the disease- related protein variant, i.e. it has significantly higher proteolytic activity on the disease- related protein variant com pared to the native human protein.
  • the disease- related protein variant is therefore detected and/or quantified by detecting and/or quantifying the activity of the target-specific protease.
  • Such detection and/or quantification is done by directly measuring the degradation products of the target protein or indirectly by measuring the influence of the target protein on the activity of the target-specific protease by a com petition assay.
  • the aim of the diagnostic test is to detect and/or quantify a protein that is specific for an infection by an infectious agent such as a virus or a bacterium .
  • an infectious agent such as a virus or a bacterium .
  • Such a diagnostic test em ploys a protease that is specific for a protein specifically expressed upon infection by the infectious agent, i.e. it has significantly higher proteolytic activity on a particular infection- indicating protein com pared to any other native human protein.
  • the infection- indicating protein is therefore detected and/or quantified by detecting and/or quantifying the proteolytic activity of the target-specific protease.
  • detection and/or quantification is done by directly measuring the degradation products of the infection- indicating protein or indirectly by measuring the influence of the infection- indicating protein on the activity of the target-specific protease by a com petition assay.
  • the engineered enzyme is used as a technical m eans in order to catalyze an industrially or nutritionally relevant reaction with defined specificity.
  • the engineered enzyme has proteolytic activity, the catalyzed reaction is a proteolytic processing, and the engineered enzym e specifically hydrolyses one or m ore industrially or nutrionally relevant protein substrates.
  • the engineered enzyme hydrolyses one or more industrially or nutrionally relevant protein substrates at specific sites, thereby leading to industrially or nutrionally desired product properties such as texture, taste or precipitation characteristics.
  • the engineered enzyme catalyzes the hydrolysis of glycosidic bonds (glycosidase or glycosylases activity) . Then, preferably, the catalyzed reaction is a polysaccharide processing, and the engineered enzyme specifically hydrolyses one or more industrially, technically or nutrionally relevant polysaccharide substrates.
  • the engineered enzyme catalyzes the hydrolysis of triglyceride esters or lipids (lipase activity) .
  • the catalyzed reaction is a lipid processing step, and the engineered enzyme specifically hydrolyses one or more industrially, technically or nutrionally relevant lipid substrates.
  • the engineered enzym e catalyzes the oxidation or reduction of substrates (oxidoreductase activity) .
  • the engineered enzyme specifically oxidizes or reduces one or more industrially, technically or nutrionally relevant chem ical substrates.
  • a second aspect of the invention discloses engineered enzymes with defined specificities. These engineered enzym es are characterized by the following com ponents:
  • SDRs specificity determ ining regions located at sites in the protein scaffold that enable the resulting engineered protein to discrim inate between at least one target substrate and one or more different substrates, wherein the SDRs are essentially synthetic peptide sequences.
  • such defined specificity of the engineered enzymes is not conferred by the protein scaffold.
  • the protein scaffold can have a variety of primary, secondary and tertiary structures.
  • the primary structure i.e. the am ino acid sequence
  • the protein scaffold is preferably of mam malian origin, and more preferably, of hum an origin.
  • the protein scaffold is capable to catalyze one or more chem ical reactions and has preferably only a low specificity.
  • derivatives of the protein scaffold are used that have modified am ino acid sequences that confer im proved characteristics for the applicability as protein scaffolds.
  • Such im proved characteristics com prise, but are not lim ited to, stability; expression or secretion yield; folding, in particular after combination of the protein scaffold with SDRs; increased or decreased sensitivity to regulators such as activators or inhibitors; im m unogenicity; catalytic rate; kM or substrate affinity.
  • the engineered enzymes reveal their quantitative specificity from the peptide sequences that are combined with the protein scaffold. Therefore, the engineered peptide sequences are acting as Specificity Determ ining Regions or SDRs.
  • the num ber, the length and the positions of such SDRs can vary over a wide range.
  • the number of SDRs within the scaffold is at least one, preferably more than one, more preferably between two and eleven, most preferably between two and six.
  • the SDRs have a length between one and 50 am ino acid residues, preferably a length between one and 15 am ino acid residues, m ore preferably a length between one and six am ino acid residues.
  • the SDRs have a length between two and 20 am ino acid residues, preferably a length between two and ten am ino acid residues, more preferably a length between three and eight am ino acid residues.
  • the inventive engineered enzymes can further be desribed as antibody-like protein molecules com prising constant and variable regions, but having a non- im m unoglogulin backbone and having an active site (catalytic activity) in the constant region, whereby the substrate specificity of the active site is modulated by the variable region.
  • the variable regions are loops of variable length and com position that interact with a target molecule.
  • the engineered enzymes have hydrolase activity.
  • the engineered enzymes have proteolytic activity.
  • Particularly preferred protein scaffolds for this variant are unspecific proteases or are parts from unspecific proteases or are otherwise derived from unspecific proteases.
  • the expressions "derived from” or "a derivative thereof” in this respect and in the following variants and embodiments refer to derivatives of proteins that are m utated at one or more am ino acid positions and/or have a homology of at least 70% , preferably 90% , m ore preferably 95% and most preferably 99% to the original protein, and/or that are proteolytically processed, and/or that have an altered glycosylation pattern, and/or that are covalently linked to non- protein substances, and/or that are fused with further protein domains, and/or that have C-term inal and/or N-term inal truncations, and/or that have specific insertions, substitutions and/or deletions.
  • derived from may refer to derivatives that are combinations or chimeras of two or more fragments from two or more proteins, each of which optionally com prises any or all of the aforementioned modifications.
  • the tertiary structure of the protein scaffold can be of any type.
  • the tertiary structure belongs to one of the following structural classes: class S1 (chymotrypsin fold of the serine proteases fam ily) , class S8 (subtilisin fold of the serine proteases fam ily) , class SC (carboxypeptidase fold of the serine proteases fam ily) , class A1 (pepsin A fold of the aspartic proteases) , or class C14 (caspase- 1 fold of the cysteine proteases) .
  • class S1 chymotrypsin fold of the serine proteases fam ily
  • class S8 subtilisin fold of the serine proteases fam ily
  • class SC carboxypeptidase fold of the serine proteases fam ily
  • class A1 pepsin A fold of the aspartic proteases
  • class C14 caspase- 1 fold of the cysteine proteases
  • Exam ples of proteases that can serve as the protein scaffold of engineered proteolytic enzymes for the use as human therapeutics are or are derived from human trypsin, human thrombin, human chymotrypsin, human pepsin, human endothiapepsin, human caspases 1 to 14, and/or human furin.
  • the defined specificity of the engineered proteolytic enzymes is a measure of their ability to discrim inate between at least one target peptide or protein substrates and one or more further peptide or protein substrates.
  • the defined specificity refers to the ability to discrim inate peptide or protein substrates that differ in other positions than the P1 site, more preferably, the defined specificity refers to the ability to discrim inate peptide or protein substrates that differ in other positions than the P1 site and the P1 ' site.
  • the engineered proteolytic enzymes distinguish target peptid or protein substrates at as many sites as is necessary to preferentially hydrolyse the target substrate versus other proteins.
  • a therapeutically useful engineered proteolytic enzyme applied intravenously in the human body should be sufficiently specific to discrim inate between the target substrate and any other protein in the human serum .
  • an engineered proteolytic enzyme recognizes and discrim inates peptide substrates at three or more am ino acid positions, more preferably at four or more positions, and even more preferably at five or m ore am ino acid positions. These positions may either be adjacent or non-adjacent.
  • the protein scaffold has a tertiary structure or fold equal or sim ilar to the tertiary structure or fold of the S1 structural subclass of serine proteases, i. e. the chymotrypsin fold, and/or has at least 70% identity on the am ino acid level to a protein of the S1 structural subclass of serine proteases.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by amino acid sequence homology to the regions 18-25, 38-48, 54-63, 73-86, 122-130, 148-156, 165-171 and 194-204 in human trypsin I, and more preferably at one or more positions from the group of positions that correspond structurally or by amino acid sequence homology to the regions 20-23, 41-45, 57-60, 76-83, 125-128, 150-153, 167-169 and 197-201 (numbering of amino acids according to SEQ ID NO:1).
  • the number of SDRs to be combined with this type of protein scaffold is preferably between 1 and 10, and more preferably between 2 and 4.
  • the protein scaffold is equal to or is a derivative or homologue of one or more of the following proteins: chymotrypsin, granzyme, kallikrein, trypsin, mesotrypsin, neutrophil elastase, pancreatic elastase, enteropeptidase, cathepsin, thrombin, ancrod, coagulation factor IXa, coagulation factor Vila, coagulation factor Xa, activated protein C, urokinase, tissue-type plasminogen activator, plasmin, Desmodus-type plasminogen activator.
  • proteins chymotrypsin, granzyme, kallikrein, trypsin, mesotrypsin, neutrophil elastase, pancreatic elastase, enteropeptidase, cathepsin, thrombin, ancrod, coagulation factor IXa, coagulation factor Vila, coagulation factor
  • the protein scaffold is trypsin or thrombin or is a derivative or homologue from trypsin or thrombin.
  • the trypsin or thrombin scaffold is most preferably of human origin in order to minimize the risk of an immune response or an allergenic reaction.
  • derivatives with improved characteristics derived from human trypsin I or from proteins with similar tertiary structure are used.
  • Preferred examples of such derivatives are derived from human trypsin I (SEQ ID NO:1) and comprise one or more of the following amino acid substitutions E56G; R78W; Y131F; A146T; C183R.
  • SDR 1 and SDR 2 sequences comprise one of the amino acid sequences listed in table 2.
  • Such engineered proteolytic enzymes have specificity for the target substrate B as exemplified in example IV.
  • the protein scaffold belongs to the S8 structural subclass of serine proteases and/or has a tertiary structure similar to subtilisin E from Bacillus subtilis_and/or has at least 70% identity on the amino acid level to a protein of the S8 structural subclass of serine proteases.
  • the scaffold belongs to the subtilisin family or the human pro-protein convertases.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 6-1 7, 25-29, 47-55, 59-69, 101 -1 1 1 , 1 17-125, 129-137, 139-1 54, 1 58- 169, 185-1 95 and 204-225 in subtilisin E from Bacillus subtilis, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 59-69, 101 -1 1 1 , 129- 137, 158-1 69 and 204-225 (numbering of am ino acids according to SEQ I D NO: 7) .
  • the protein scaffold is equal to or is a derivative or hom ologue of one or more of the following proteins: subtilisin Carlsberg; B. subtilis subtilisin E; subtilisin BPN'; B. licheniform is subtilisin ; B. lentus subtilisin; Bacillus alcalophilus alkaline protease; proteinase K; kexin ; human pro- protein convertase; human furin. I n a preferred variant, subtilisin BPN' or one of the proteins SPC 1 to 7 is used as the protein scaffold.
  • the protein scaffold belongs to the fam ily of aspartic proteases and/or has a tertiary structure sim ilar to human pepsin.
  • the scaffold belongs to the A1 class of proteases and/or has at least 70% identity on the am ino acid level to a protein of the A1 class of proteases.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 6-18, 49-55, 74-83, 91 -97, 1 12- 120, 126-137, 159-164, 1 84-194, 242- 247, 262-267 and 277-300 in human pepsin, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 10-1 5, 75-80, 1 14-1 1 8, 130-134, 186-1 91 and 280-296 (numbering of am ino acids according to SEQ I D NO: 1 1 ) .
  • the protein scaffold is equal to or is a derivative or homologue of one or m ore of the following proteins: pepsin, chymosin, renin, cathepsin, yapsin.
  • pepsin or endothiopepsin or a derivative or homologue thereof is used as the protein scaffold.
  • the protein scaffold belongs to the cysteine protease fam ily and/or has a tertiary structure sim ilar to human caspase 7.
  • the scaffold belongs to the C14 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C14 class of cysteine proteases.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 78-91 , 144-1 60, 1 86-198, 226-243 and 271 -291 in human caspase 7, and m ore preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 80-86, 149-157, 1 90-194 and 233-238 (numbering of am ino acids according to SEQ I D NO: 14) .
  • the protein scaffold is equal to or is a derivative or hom ologue of one of the caspases 1 to 9.
  • the protein scaffold belongs to the S1 1 class of serine proteases or has at least 70% identity on the am ino acid level to a protein of the S1 1 class of serine proteases and/or has a tertiary structure sim ilar to D-alanyl- D- alanine transpeptidase from Streptomyces species K15.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 67-79, 137-150, 191 -206, 212-222 and 241 -251 in D-alanyl- D-alanine transpeptidase from Streptomyces species K15, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 70-75, 141 -147, 195-202 and 216-220 (numbering of am ino acids according to SEQ I D NO: 15) . It is preferred that the D- alanyl- D-alanine transpeptidase from Streptomyces species K15 or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the S21 class of serine proteases or has at least 70% identity on the am ino acid level to a protein of the S21 class of serine proteases and/or has a tertiary structure sim ilar to assemblin from human cytomegalovirus.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 25-33, 64-69, 134- 1 55, 1 62- 169 and 217-244 in assemblin from human cytomegalovirus, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 27-31 , 164-1 68 and 222-239 (numbering of am ino acids according to SEQ I D NO: 1 6) . It is preferred that the assemblin from human cytomegalovirus or a derivative or homologue thereof is used as the scaffold.
  • I n a further embodim ent the protein scaffold belongs to the S26 class of serine proteases or has at least 70% identity on the am ino acid level to a protein of the S26 class of serine proteases and/or has a tertiary structure sim ilar to the signal peptidase from Escherichia coli.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 8-14, 57-68, 125-134, 239-254, 200-21 1 and 228-239 in signal peptidase from Escherichia coli, and more preferably at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 9- 13, 60-67, 127- 132 and 203-209 (numbering of am ino acids according to SEQ I D NO: 1 7) . It is preferred that the signal peptidase from Escherichia coli or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the S33 class of serine proteases or has at least 70% identity on the am ino acid level to a protein of the S33 class of serine proteases and/or has a tertiary structure sim ilar to the prolyl am inopeptidase from Serratia marcescens.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 47-54, 152-160, 203-212 and 297-302 in prolyl am inopeptidase from Serratia marcescens, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 50-53, 154-1 58 and 206-21 0 (numbering of am ino acids according to SEQ I D NO: 1 8) . It is preferred that the prolyl am inopeptidase from Serratia marcescens or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the S51 class of serine proteases or has at least 70% identity on the am ino acid level to a protein of the S51 class of serine proteases and/or has a tertiary structure sim ilar to aspartyl dipeptidase from Escherichia coli.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 8-16, 38-46, 85-92, 132- 140, 159-170 and 205-21 1 in aspartyl dipeptidase from Escherichia coli, and more preferably at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 10-14, 87-90, 134-138 and 1 60-165 (numbering of am ino acids according to SEQ I D NO: 1 9) . It is preferred that the aspartyl dipeptidase from Escherichia coli or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the A2 class of aspartic proteases or has at least 70% identity on the am ino acid level to a protein of the A2 class of aspartic proteases and/or has a tertiary structure sim ilar to the protease from human im m unodeficiency virus.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 5-12, 1 7-23, 27-30, 33-38 and 77-83 in protease from human im m unodeficiency virus, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 7-10, 1 8-21 , 34-37 and 79-82 (numbering of am ino acids according to SEQ I D NO: 20) .
  • the protease from human im m unodeficiency virus preferably HIV- 1 protease, or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the A26 class of aspartic proteases or has at least 70% identity on the am ino acid level to a protein of the A26 class of aspartic proteases and/or has a tertiary structure sim ilar to the om ptin from Escherichia coli.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 28-40, 86-98, 1 50-168, 213-219 and 267-278 in om ptin from Escherichia coli, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 33-38, 161 -168 and 273-277 (numbering of am ino acids according to SEQ I D NO: 21 ) . It is preferred that the om ptin from Escherichia coli or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the C1 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C1 class of cysteine proteases and/or has a tertiary structure sim ilar to the papain from Carica papaya.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 17-24, 61 -68, 88-95, 135-142, 153-158 and 176-184 in papain from Carica papaya, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 63-66, 136-139 and 177-1 81 (numbering of am ino acids according to SEQ I D NO: 22) . It is preferred that the papain from Carica papaya or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the C2 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C2 class of cysteine proteases and/or has a tertiary structure sim ilar to human calpain-2.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 90-103, 160-1 72, 1 93- 199, 243-260, 286- 294 and 31 6-322 in human calpain-2, and m ore preferably at one or more positions from the group of positio ns that correspond structurally or by am ino acid sequence homology to the regions 92-101 , 245-250 and 287-291 (numbering of am ino acids according to SEQ I D NO:23) . It is preferred that the human calpain-2 or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the C4 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C4 class of cysteine proteases and/or has a tertiary structure sim ilar to NI a protease from tobacco etch virus.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 23-31 , 1 12-120, 144-150, 168-1 76 and 205-218 in NI a protease from tobacco etch virus, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 145- 149, 169-174 and 212-21 8 (num bering of am ino acids according to SEQ I D NO: 24) .
  • the NI a protease from tobacco etch virus (TEV protease) or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the C10 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C1 0 class of cysteine proteases and/or has a tertiary structure sim ilar to the streptopain from Streptococcus pyogenes.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 81 -90, 133-140, 1 50- 164, 191 -199, 219-229, 246-256, 306-312 and 330-337 in streptopain from Streptococcus pyogenes, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 82-87, 134-138, 250-254 and 331 -335 (numbering of am ino acids according to SEQ I D NO:25) . It is preferred that the streptopain from Streptococcus pyogenes or a derivative or hom ologue thereof is used as the scaffold.
  • I n a further embodim ent the protein scaffold belongs to the C19 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C19 class of cysteine proteases and/or has a tertiary structure sim ilar to human ubiquitin specific protease 7.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 3- 15, 63-70, 80- 86, 248-256, 272-283 and 292-304 in hum an ubiquitin specific protease 7, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 0-15, 251 -255, 277-281 and 298-304 (numbering of am ino acids according to SEQ I D NO: 26) . It is preferred that the human ubiquitin specific protease 7 or a derivative or homologue thereof is used as the scaffold.
  • I n a further embodim ent the protein scaffold belongs to the C47 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C47 class of cysteine proteases and/or has a tertiary structure sim ilar to the staphopain from Staphylococcus aureus.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 5-23, 57-66, 1 08- 1 19, 142-149 and 157-1 64 in staphopain from Staphylococcus aureus, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 7-22, 1 1 1 -1 17, 143-147 and 1 59-163 (numbering of am ino acids according to SEQ I D NO: 27) . It is preferred that the staphopain from Staphylococcus aureus or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the C48 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C48 class of cysteine proteases and/or has a tertiary structure sim ilar to the Ulp1 endopeptidase from Saccharomyces cerevisiae.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 40-51 , 1 08- 1 15, 132-141 , 1 73-179 and 597-605 in Ulp1 endopeptidase from Saccharomyces cerevisiae, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 43-49, 1 1 0- 1 13, 133-137 and 1 75-178 (numbering of am ino acids according to SEQ I D NO:28) . It is preferred that the Ulp1 endopeptidase from Saccharomyces cerevisiae or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the C56 class of cysteine proteases or has at least 70% identity on the am ino acid level to a protein of the C56 class of cysteine proteases and/or has a tertiary structure sim ilar to the RpI endopeptidase from Pyrococcus horikoshii.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 8-16, 40-47, 66-73, 1 1 8- 125 and 147-153 in RpI endopeptidase from Pyrococcus horikoshii, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 9- 14, 68-71 , 120- 123 and 148-151 (numbering of am ino acids according to SEQ I D NO:29) . It is preferred that the RpI endopeptidase from Pyrococcus horikoshii or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the M4 class of metallo proteases or has at least 70% identity on the am ino acid level to a protein of the M4 class of metallo proteases and/or has a tertiary structure sim ilar to therm olysin from Bacillus thermoproteolyticus.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 06- 1 18, 125-130, 152-160, 1 97-204, 210-213 and 221 -229 in thermolysin from Bacillus thermoproteolyticus, and more preferably at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 08-1 15, 126-129, 199-203 and 223-227 (num bering of am ino acids according to SEQ I D NO: 30) . It is preferred that the thermolysin from Bacillus thermoproteolyticus or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the M1 0 class of metallo proteases or has at least 70% identity on the am ino acid level to a protein of the M1 0 class of metallo proteases and/or has a tertiary structure sim ilar to human collagenase.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 2-7, 68-79, 85-90, 107-1 1 1 and 135-141 in human collagenase, and more preferably at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 3-6, 71 -78 and 136- 140 (num bering of am ino acids according to SEQ I D NO: 31 ) . It is preferred that human collagenase or a derivative or homologue thereof is used as the scaffold.
  • the engineered enzymes have glycosidase activity.
  • a particularly suited protein scaffold for this variant is a glycosylase or is derived from a glycosylase.
  • the tertiary structure belongs to one of the following structural classes: class GH13, GH7, GH12, GH1 1 , GH10, GH28, GH26, and GH18 (beta/alpha)8 barrel.
  • the protein scaffold belongs to the GH13 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH13 class of glycosylases and/or has a tertiary structure sim ilar to human pancreatic alpha- amylase.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 50-60, 1 00- 1 1 0, 148- 167, 235-244, 302- 31 0 and 346-359 in human pancreatic alpha-amylase, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 51 -58, 148- 155 and 303-309 (numbering of am ino acids according to SEQ I D NO:32) . It is preferred that human pancreatic alpha-amylase or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH7 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH7 class of glycosylases and/or has a tertiary structure sim ilar to cellulase from Trichoderma reesei.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 47-56, 93- 1 04, 173-182, 215- 223, 229-236 and 322-334 in cellulase from Trichoderma reesei, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 175-180, 218-222 and 324-332 (numbering of am ino acids according to SEQ I D NO:33) . It is preferred that cellulase from Trichoderma reesei or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH12 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH12 class of glycosylases and/or has a tertiary structure sim ilar to cellulase from Aspergillus niger.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 18-28, 55-60, 106-1 13, 126- 132 and 149-159 in cellulase from Aspergillus niger, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 20-26, 56-59, 108-1 12 and 151 -156 (num bering of am ino acids according to SEQ I D NO: 34) . It is preferred that cellulase from Aspergillus niger or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH1 1 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH1 1 class of glycosylases and/or has a tertiary structure sim ilar to xylanase from Aspergillus niger.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 7-1 4, 33-39, 88-97, 1 14-126 and 158-167 in xylanase from Aspergillus niger, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 20-26, 56-59, 108-1 12 and 151 -1 56 (numbering of am ino acids according to SEQ I D NO:35) . It is preferred that xylanase from Aspergillus niger or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH10 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH10 class of glycosylases and/or has a tertiary structure sim ilar to xylanase from Streptomyces lividans.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 21 -29, 42-50, 84- 92, 130- 136, 206-21 7 and 269-278 in xylanase from Streptomyces lividans, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 43-49, 86-90, 208-213 and 271 -276 (numbering of am ino acids according to SEQ I D NO: 36) . It is preferred that xylanase from Streptomyces lividans or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH28 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH28 class of glycosylases and/or has a tertiary structure sim ilar to pectinase from Aspergillus niger.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 82-88, 1 1 8- 126, 1 71 - 1 78, 228-236, 256-264 and 289-299 in pectinase from Aspergillus niger, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 1 6-124, 174-178 and 291 -296 (num bering of am ino acids according to SEQ I D NO: 37) . It is preferred that pectinase from Aspergillus niger or a derivative or hom ologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH26 class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH26 class of glycosylases and/or has a tertiary structure sim ilar to mannanase from Pseudomonas cellulosa.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 75-83, 1 13-125, 174-1 82, 21 7-224, 247-254, 324-332 and 325-340 in mannanase from Pseudomonas cellulosa, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 1 15-123, 176-1 80, 286-291 and 328-337 (numbering of am ino acids according to SEQ I D NO: 38) . It is preferred that mannanase from Pseudomonas cellulosa or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GH18 (beta/alpha)8 barrel class of glycosylases or has at least 70% identity on the am ino acid level to a protein of the GH18 class of glycosylases and/or has a tertiary structure sim ilar to chitinase from Bacillus circulans.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 21 -29, 57-65, 130-136, 1 76- 183, 221 -229, 249-257 and 327-337 in chitinase from Bacillus circulans, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 59-63, 178-181 , 250-254 and 330-336 (numbering of am ino acids according to SEQ I D NO: 39) . It is preferred that chitinase from Bacillus circulans or a derivative or homologue thereof is used as the scaffold.
  • the engineered enzymes have esterhydrolase activity.
  • the protein scaffold for this variant have lipase, phosphatase, phytase, or phosphodiesterase activity.
  • the protein scaffold belongs to the GX class of esterases or has at least 70% identity on the am ino acid level to a protein of the GX class of esterases and/or has a tertiary structure sim ilar to the structure of the lipase B from Candida antarctica.
  • the scaffold has lipase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 139- 148, 1 88- 195, 216-224, 256-266, 272-287 in lipase B from Candida antarctica, and m ore preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 141 -146, 21 8-222, 259-263 and 275-283 (numbering of am ino acids according to SEQ I D NO: 40) . It is preferred that lipase B from Candida antarctica or a derivative or hom ologue thereof is used as the scaffold.
  • the protein scaffold belongs to the GX class of esterases or has at least 70% identity on the am ino acid level to a protein of the GX class of esterases and/or has a tertiary structure sim ilar to the pancreatic lipase from guinea pig.
  • the scaffold has lipase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 78-90, 91 -100, 1 12- 120, 179-1 86, 207-218, 238-247 and 248-260 in pancreatic lipase from guinea pig, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 80-87, 1 14- 1 18, 209-215 and 239-246 (numbering of am ino acids according to SEQ I D NO: 41 ) . It is preferred that pancreatic lipase from guinea pig or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the alkaline phosphatase from Escherichia coli or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the alkaline phosphatase from Escherichia coli.
  • the scaffold has phosphatase activity.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 1 1 0- 122, 187-142, 1 70-175, 186-1 93, 280-287 and 425-435 in alkaline phosphatase from Escherichia coli, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 71 - 174, 187-1 91 , 282-286 and 426-433 (numbering of am ino acids according to SEQ I D NO: 42) . It is preferred that alkaline phosphatase from Escherichia coli or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the bovine pancreatic desoxyribonuclease I or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the bovine pancreatic desoxyribonuclease I .
  • the scaffold has phosphodiesterase activity. More preferably, a nuclease, and most preferably, an unspecific endonuclease or a derivative thereof is used as the scaffold.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 14-21 , 41 -47, 72-77, 97-1 1 1 , 135-143, 171 -178, 202-209 and 242-251 in bovine pancreatic desoxyribonuclease I , and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 16-19, 42-46, 136- 141 and 172-1 76 (numbering of am ino acids according to SEQ I D NO: 43) . It is preferred that bovine pancreatic desoxyribonuclease I or human desoxyribonuclease I or a derivative or homologue thereof is used as the scaffold.
  • the engineered enzyme has transferase activity.
  • a particularly suited protein scaffold for this variant is a glycosyl- , a phospho- or a methyltransferase, or is a derivative thereof.
  • Particularly preferred protein scaffolds for this variant are glycosyltransferases or are derived from glycosyltransferases.
  • the tertiary structure of the protein scaffold can be of any type. Preferably, however, the tertiary structure belongs to one of the following structural classes: GH13 and GT1 .
  • the protein scaffold belongs to the GH13 class of transferases or has at least 70% identity on the am ino acid level to a protein of the GH13 class of transferases and/or has a tertiary structure sim ilar to the structure of the cyclomaltodextrin glucanotransferase from Bacillus circulans.
  • the scaffold has transferase activity, and more preferably a glycosyltransferase is used as the scaffold.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 38-48, 85-94, 142-1 54, 1 78-186, 259-266, 331 -340 and 367-377 in cyclomaltodextrin glucanotransferase from Bacillus circulans, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 87-92, 180-185, 261 -264 and 269-275 (numbering of am ino acids according to SEQ I D NO: 44) .
  • the protein scaffold belongs to the GT1 class of tranferases or has at least 70% identity on the am ino acid level to a protein of the GT1 class of transferases and/or has a tertiary structure sim ilar to the structure of the glycosyltransferase from Amycolatopsis orientalis A82846.
  • the scaffold has transferase activity, and more preferably glycosyltransferase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 58-74, 130- 138, 185- 193, 228-236 and 314-323 in glycosyltransferase from Amycolatopsis orientalis A82846, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 61 -71 , 230-234 and 316-321 (num bering of am ino acids according to SEQ I D NO: 45) . It is preferred that the glycosyltransferase from Amycolatopsis orientalis A82846 or a derivative or homologue thereof is used as the scaffold.
  • the engineered enzymes have oxidoreductase activity.
  • a particularly suited protein scaffold for this variant is a monooxygenase, a dioxygenase or a alcohol dehydrogenase, or a derivative thereof.
  • the tertiary structure of the protein scaffold can be of any type.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the 2,3 -diphydroxybiphenyl dioxygenase from Pseudomonas sp. or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the 2,3 -diphydroxybiphenyl dioxygenase from Pseudomonas sp.
  • the scaffold has dioxygenase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 172- 185, 198-206, 231 -237, 250-259 and 282-287 in 2,3- diphydroxybiphenyl dioxygenase from Pseudomonas sp. , and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 175-182, 200-204, 252-257 and 284-287 (numbering of am ino acids according to SEQ I D NO:46) . It is preferred that the 2,3 -diphydroxybiphenyl dioxygenase from Pseudomonas sp or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the catechol dioxygenase from Acinetobacter sp. or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the catechol dioxygenase from Acinetobacter sp..
  • the scaffold has dioxygenase activity, and more preferably catechol dioxygenase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 66-72, 1 05-1 12, 1 56-171 and 198-207 in catechol dioxygenase from Acinetobacter sp., and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 107- 1 10, 161 -171 and 201 -205 (num bering of am ino acids according to SEQ I D NO: 47) . It is preferred that the catechol dioxygenase from Acinetobacter sp or a derivative or hom ologue thereof is used as the scaffold.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the cam phor-5- monooxygenase from Pseudomonas putida or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the cam phor-5-monooxygenase from Pseudomonas putida.
  • the scaffold has monooxygenase activity, and m ore preferably cam phor monooxygenase activity.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 26-31 , 57-63, 84-98, 1 82- 191 , 242-256, 292-299 and 392-399 in cam phor-5- monooxygenase from Pseudom onas putida, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 85-96, 183- 188, 244-253, 293-298 and 393-398 (num bering of am ino acids according to SEQ I D NO: 48) . It is preferred that the cam phor-5-monooxygenase from Pseudomonas putida or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the alcohol dehydrogenase from Equus callabus or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the alcohol dehydrogenase from Equus callabus.
  • the scaffold has alcohol dehydrogenase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 49-63, 1 1 1 -1 12, 294-301 and 361 -369 in alcohol dehydrogenase from Equus callabus, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 51 -61 and 295-299 (numbering of am ino acids according to SEQ I D NO:49) . It is preferred that the alcohol dehydrogenase from Equus callabus or a derivative or homologue thereof is used as the scaffold.
  • the engineered enzymes have lyase activity.
  • a particularly suited protein scaffold for this variant is a oxoacid lyase or is a derivative thereof .
  • Particularly preferred protein scaffolds for this variant are aldolases or synthases, or are derived thereof.
  • the tertiary structure of the protein scaffold can be of any type, but a (beta/alpha)8 barrel structure is preferred.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the N-acetyl-d- neuram ic acid aldolase from Escherichia coli or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the N-acetyl-d- neuram ic acid aldolase from Escherichia coli.
  • the scaffold has aldolase activity.
  • SDRs are inserted into the protein scaffold at one or m ore positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 45-55, 78-87, 105-1 13, 137-146, 1 64- 171 , 187-1 93, 205-210, 244-255 and 269-276 in N-acetyl-d- neuram ic acid aldolase from Escherichia coli, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 45-52, 138-144, 189-1 92, 247-253 and 271 -275 (numbering of am ino acids according to SEQ I D NO: 50) . It is preferred that the N-acetyl-d- neuram ic acid aldolase from Escherichia coli or a derivative or homologue thereof is used as the scaffold.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the trypto phan synthase from Salmonella typhim urium or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the tryptophan synthase from Salmonella typhim urium .
  • the scaffold has synthase activity.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 56-63, 127-134, 1 54-161 , 175-1 93, 209-21 6 and 230-240 in tryptophan synthase from Salmonella typhim urium , and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 57-62, 155-1 60, 1 78- 190 and 210-215 (numbering of am ino acids according to SEQ I D NO: 51 ) . It is preferred that the tryptophan synthase from Salmonella typhim urium or a derivative or homologue thereof is used as the scaffold.
  • engineered enzym es have isomerase activity.
  • a particularly suited protein scaffold for this variant is a converting aldose or a converting ketose, or is a derivative thereof.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the xylose isomerase from Actinoplanes m issouriensis or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the xylose isomerase from Actinoplanes m issouriensis.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 1 8-31 , 92- 103, 136-147, 1 78-188 and 250-257 in xylose isomerase from Actinoplanes m issouriensis, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 20-27, 92-99 and 180-1 86 (num bering of am ino acids according to SEQ I D NO: 52) . It is preferred that the xylose isomerase from Actinoplanes m issouriensis or a derivative or hom ologue thereof is used as the scaffold.
  • the engineered enzymes have ligase activity.
  • a particularly suited protein scaffold for this variant is a DNA ligase, or is a derivative thereof.
  • the protein scaffold has a tertiary structure sim ilar to the structure of the DNA ligase from Bacteriophage T7 or has at least 70% identity on the am ino acid level to a protein that has a tertiary structure sim ilar to the structure of the DNA- ligase from Bacteriophage T7.
  • SDRs are inserted into the protein scaffold at one or more positions from the group of positions that correspond structurally or by am ino acid sequence homology to the regions 52-60, 94-1 08, 1 1 9- 131 , 241 -248, 255-263 and 302-318 in DNA ligase from Bacteriophage T7, and more preferably at one or more positions from the group of positions that correspond structurally or by am ino acid sequence hom ology to the regions 96-106, 121 -1 29, 256-262 and 304-316 (numbering of am ino acids according to SEQ I D NO: 53) . It is preferred that the DNA ligase from Bacteriophage T7 or a derivative or homologue thereof is used as the scaffold.
  • a third aspect of the invention is directed to a m ethod for generating engineered enzymes with specificities that are qualitatively and/or quantitatively novel in combination with the protein scaffold.
  • the inventive method com prises at least the following steps:
  • step (b) generating a library of engineered enzymes or isolated engineered enzymes by combining the protein scaffold from step (a) with one or more fully or partially random peptide sequences at sites in the protein scaffold that enable the resulting engineered enzym e to discrim inate between at least one target substrate and one or m ore different substrates and
  • step (c) selecting out of the library of engineered enzymes generated in step (b) one or more enzymes that have defined specificities towards at least one target substrate.
  • the inventive method com prises at least the following steps:
  • step (b) generating a library of engineered enzymes or isolated engineered enzymes by inserting into the protein scaffold from step (a) one or more fully or partially random peptide sequences at sites in the protein scaffold that enable the resulting engineered enzym e to discrim inate between at least one target substrate and one or m ore different substrates and
  • step (c) selecting out of the library of engineered enzymes generated in step (b) one or m ore enzymes that have defined specificities towards at least one target substrate.
  • the positions at which the one or more fully or partially random peptide sequences are combined with or inserted into the protein scaffold are identified prior to the combination or insertion.
  • the number of insertions or other combinations of fully or partially random peptide sequences as well as their length may vary over a wide range.
  • the num ber is at least one, preferably more than one, more preferably between two and eleven, most preferably between two and six.
  • the length of such fully or partially random peptide sequences is usually less than 50 am ino acid residues.
  • the length is between one and 15 am ino acid residues, more preferably between one and six am ino acid residues.
  • the length is between two and 20 am ino acid residues, preferably between two and ten am ino acid residues, more preferably between three and eight am ino acid residues.
  • such insertions or other combinations are perform ed on the DNA level, using polynucleotides encoding such protein scaffolds and polynucleotides or oligonucleotides encoding such fully or partially random peptide sequences.
  • steps (a) to (c) are repeated cyclically, whereby enzymes selected in step (c) serve as the protein scaffold in step (a) of a further cycle, and random ized peptide sequences are either inserted or, alternatively, substituted for peptide sequences that have been inserted in former cycles. Thereby, the number of inserted peptide sequences is either constant or increases over the cycles. The cycles are repeated until one or more enzymes with the intended specificities are generated.
  • the scaffold may be m utated at one or more positions in order to make the scaffold more acceptable for the combination with SDR sequences, and/or to increase catalytic activity at a specific pH and tem perature, and/or to change the glycosylation pattern, and/or to decrease sensitivity towards enzym e inhibitors, and/or to change enzyme stability.
  • the inventive method com prises at least the following steps:
  • step (c) connecting the product of step (b) via a peptide linkage with a further SDR peptide or with a further protein scaffold fragment, and optionally
  • step (d) repeating step (c) for as many cycles as necessary in order to generate a sufficiently specific enzyme
  • a protein scaffold is com prised of at least two protein scaffold fragments.
  • the protein scaffold, the SDRs and the engineered enzym e are encoded by a DNA sequence and an expression system is used in order to produce the protein.
  • the protein scaffold, the SDRs and/or the engineered enzym e are chem ically synthesized from peptide building blocks.
  • the inventive m ethod com prises at least the following steps:
  • step (c) selecting out of the population generated in step (b) one or more polynucleotides that encode enzymes that have the defined specificities toward the one or more target substrates.
  • any enzym e can serve as the protein scaffold in step (a) . It can be a naturally occurring enzyme, a variant or a truncated derivate therefore, or an engineered enzyme.
  • the protein scaffold is preferably a m am malian enzyme, and more preferably a human enzyme.
  • the invention is directed to a method for the generation of essentially mam m alian, especially of essentially human enzymes with specificities that are different from specificities of any enzym e encoded in mam malian genom es or in the human genome, respectively.
  • the protein scaffold provided in step (a) of this aspect requires to be capable of catalyzing one or more chem ical reactions on a target substrate. Therefore, a protein scaffold is selected from the group of potential protein scaffolds by its activity on the target substrate.
  • a protein scaffold with hydrolase activity is used.
  • a protein scaffold with proteolytic activity is used, and m ore preferably, a protease with very low specificity having basic activity on the target substrate is used as the protein scaffold.
  • Exam ples of proteases from different structural classes with low substrate specificity are Papain, Trypsin, Chymotrypsin, Subtilisin, SET (trypsin- like serine protease from Streptomyces erythraeus) , Elastase, Cathepsin G or Chymase.
  • am ino acid sequence of the protease may be modified in order to change protein properties other than specificity, e.g catalytic activity, stability, inhibitor sensitivity, or expression yield, essentially as described in WO 92/ 18645, or in order to change specificity, essentially as described in EP 02020576.3 and PCT/ EP03/ 04864.
  • lipases Another option for a feasible protein scaffold are lipases. Hepatic lipase, lipoprotein lipase and pancreatic lipase belong to the "lipoprotein lipase superfam ily", which in turn is an exam ple of the GX-class of lipases ( M. Fischer, J. Pleiss (2003) , Nucl. Acid. Res. , 31 , 319-321 ) .
  • the substrate specificity of lipases can be characterized by their relative activity towards triglycerol esters of fatty acids and phospholipids, bearing a charged head group.
  • hydrolases such as esterases, glycosylases, am idases, or nitrilases may be used as scaffolds.
  • Transferases are also feasible protein scaffolds. Glycoslytransferases are involved in many biological synthesis involving a variety of donors and acceptors. Alternatively, the protein scaffold may have ligase, lyase, oxidoreductase, or isomerase activity.
  • the one or more fully or partially random peptide sequences are inserted at specific sites in the protein scaffold. These insertion sit es are characterized by the fact that the inserted peptide sequences can act as discrim inators between different substrates, i.e. as Specificity Determ ining Regions or SDRs. Such insertion sites can be identified by several approaches. Preferably, insertio n sites are identified by analysis of the three-dim ensional structure of the protein scaffolds, by com parative analysis of the primary sequences of the protein scaffold with other enzymes having different quantitative specificities, or experimentally by techniques such as alanine scanning, random m utagenesis, or random deletion, or by any combination thereof.
  • I n a second approach to identify insertion sites for SDRs, three-dimensional structures of the scaffold protein in com plex with com petitive inhibitors or substrate analogs are analysed. It is assumed that the binding site of a com petitive inhibitor significantly overlaps with the binding site of the substrate. I n that case, atoms of the protein that are within a certain distance of atoms of the inhibitor are likely to be in a sim ilar distance to the substrate as well. Choosing a short distance, e.g. ⁇ 5 A, will result in an ensemble of protein atoms that are in close contact with the substrate. These residues would constitute the first shell contacts and are therefore preferred insertion sites for SDRs. Once first shell contacts have been identified, second shell contacts can be found by repeating the distance analysis starting from first shell atoms. I n yet another alternative of the invention the distance analysis described above is perform ed starting from the active site residues.
  • Such an alignment may reveal conserved and non-conserved regions with varying sequence homology, and, in particular, additional sequence elem ents in one or more enzymes com pared to the scaffold protein.
  • conserved regions of are m ore likely to contribute to phenotypes shared among the different proteins, e.g. stabilizing the three-dimensional fold.
  • Non-conserved regions and, in particular, additional sequences in enzymes with quantitatively higher specificity are preferred insertion sites for SDRs.
  • proteases currently five fam ilies are known, namely aspartic- , cysteine- , serine- , metallo- and threonine proteases. Each fam ily includes groups of proteases that share a sim ilar fold. Crystallographic structures of members of these groups have been solved and are accessible through public databases, e.g. the Brookhaven protein database ( H. M. Berman et al. Nucleic Acids Research, 28 pp. 235-242 (2000) ) . Such databases also include structural homologs in other enzyme classes and nonenzymatically active proteins of each class.
  • SCOP - a structural classification of proteins database for the investigation of sequences and structures.
  • serine proteases of the structural class S1 are compared with each other. Trypsin represents a member with low substrate specificity, as it requires only an arginine or lysine residue at the Pi position.
  • thrombin, tissue-type plasminogen activator or enterokinase all have a high specificity towards their substrate sequences, i.e. (L/I/V/F)XPR ⁇ NA, CPGR ⁇ VVGG and DDDK ⁇ , respectively (Perona, J. & Craik, C. (1997) J. Biol. Chem., 272, 29987-29990; Perona, J. & Craik, C (1995) Protein Science, 4, 337- 360).
  • An alignment of the amino acid sequences of these proteases is described in example 1 ( Figure 2) along with the identification of SDRs.
  • Subtilisin is the type protease for this class and represents an unspecific protease (Ottesen,M. & Svendsen,A. (1998) Methods Enzymol. 19, 199-215).
  • Furin, PC1 and PC5 are proteases of the same structural class involved in the processing of propeptides and have a high substrate specificity (Seidah, N. & Chretien, M. (1997) Curr. Opin. Biotech., 8: 602-607; Bergeron, F. et al. (2000) J. MoI. Endocrin., 24:1-22).
  • aspartic acid proteases of the structural class A1 are analyzed ( Rawlings, N. D. & Barrett, A.J. ( 1995) . Methods Enzymol. 248, 105-120; Chitpinityol, S. & Crabbe, MJ. ( 1 998) , Food Chemistry, 61 , 395-418) .
  • Exam ples for the A1 structural class of aspartic proteases are pepsin with a low as well as beta-secretase (Gr ⁇ ninger- Leitch, F., et al. (2002) J. Biol. Chem. 277, 4687-4693) and renin (Wang, W. & Liang, TC.
  • Retroviral proteases also belong to this class, although the active enzyme is a dimer of two identical subunits.
  • the viral proteases are essential for the correct processing of the polyprotein precursor to generate functional proteins which requires a high substrate specificity in each case (Wu, J. et al. ( 1 998) Biochemistry, 37, 4518- 4526; Pettit, S. et al. ( 1 991 ) J. Biol. Chem . , 266, 14539- 14547) .
  • Pepsin is the type protease for this class and represents an unspecific protease ( Kageyama, T. (2002) Cell. MoI. Life Sci.
  • B-secretase and Cathepsin D are proteases of the same structural class and have a high substrate specificity.
  • I n a preferred variant of the approach alignments of the prim ary am ino acids sequences ( Figure 6) are used to identify six sequence stretches longer than three am ino acids which are inserted in the specific proteases com pared to pepsin and are therefore potential specificity determ ining regions.
  • I n a further variant of the approach information from the three- dimensional structure of b-secretase can be used in order to further narrow down the selection.
  • caspase-1 , caspase-3 and caspase-9 recognize the sequences YVAD ⁇ , DEVD ⁇ or LEHD ⁇ , respectively. Identification of the regions that differ between the caspases will include the regions responsible for the differences in substrate specificity ( Figures 7 and 8) .
  • non-enzymatic proteins of the same fold as the enzyme scaffold m ay also contribute to the identification of insertion sites for SDRs.
  • haptoglobin Arcoleo, J. & Greer, J. ; ( 1 982) J. Biol. Chem . 257, 1 0063- 10068
  • azurocidin Almeida, R. et al. ( 1991 ) Biochem . Biophys. Res. Com m un. 177, 688-695
  • I n a fourth approach, insertion sites for SDRs are identified experim entally by techniques such as alanine scanning, random m utagenesis, random insertion or random deletion.
  • I n contrast to the approach disclosed above, this approach does not require detailed knowledge about the three-dimensional structure of the scaffold protein.
  • random m utagenesis of enzymes with relatively high specificity from the same structural class as the protein scaffold and screening for loss or change of specificity can be used to identify insertion sites for SDRs in the protein scaffold.
  • Random m utagenesis, alanine scanning, random insertion or random deletion are all done on the level of the polynucleotides encoding the enzymes.
  • There are a variety of protocols known in the literature e.g. Sambrook, J. F; Fritsch, E. F. ; Maniatis,T. ; Cold Spring Harbor Laboratory Press, Second Edition, 1 989, New York
  • random m utagenesis can be achieved by the use of a polymerase as described in patent WO 9218645.
  • the one or more genes encoding the one or more proteases are am plified by use of a DNA polymerase with a high error rate or under conditions that increase the rate of m isincorporations.
  • a DNA polymerase with a high error rate or under conditions that increase the rate of m isincorporations.
  • Cadwell and Joyce can be em ployed (Cadwell, R.C. and Joyce, G. F., PCR m ethods. Appl. 2 ( 1 992) 28-33) .
  • Other methods of random m utagenesis such as, but not lim ited to, the use of m utator stains, chem ical m utagens or UV- radiation can be em ployed as well.
  • oligonucleotides can be used for m utagenesis that substitute random ly distributed am ino acid residues with an alanine.
  • This method is generally referred to as alanine scanning m utagenesis (Fersht, A. R. Biochem istry ( 1989) 8031 -8036) .
  • modifications of the alanine scanning m utagenesis such as binom inal m utagenesis (Gregoret, L. M. and Sauer, RT. PNAS ( 1993) 4246-4250) or com binatorial alanine scanning (Weiss et al., PNAS (2000) 8950-8954) can be em ployed.
  • the DNA encoding such engineered proteins is ligated into a suitable expression vector by standard molecular cloning techniques (e.g. Sam brook, J. F; Fritsch, E. F. ; Maniatis, T. ; Cold Spring Harbor Laboratory Press, Second Edition, 1 989, New York) .
  • the vector is introduced in a suitable expression host cell, which expresses the corresponding engineered enzyme variant.
  • Particularly suitable expression hosts are bacterial expression hosts such as Escherichia coli or Bacillus subtilis, or yeast expression hosts such as Saccharomyces cerevisae or Pichia pastoris, or mam malian expression hosts such as Chinese Hamster Ovary (CHO) or Baby Hamster Kidney ( BHK) cell lines, or viral expression systems such as bacteriophages like M13 or Lambda, or viruses such as the Baculovirus expression system .
  • systems for in vitro protein expression can be used.
  • the DNA is ligated into an expression vector behind a suitable signal sequence that leads to secretion of the enzyme variants into the extracellular space, thereby allowing direct detection of protease activity in the cell supernatant.
  • Particularly suitable signal sequences for Escherichia coli are HIyA, for Bacillus subtilis AprE, NprB, Mpr, AmyA, AmyE, Blac, SacB, and for S. cerevisiae BaM , Suc2, Mat ⁇ , I nui A, Ggplp.
  • the enzyme variants are expressed intracellular ⁇ and the substrates are expressed also intracellular ⁇ .
  • this is done essentially as described in patent application WO 0212543, using a fusion peptide substrate com prising two auto-fluorescent proteins linked by the substrate am ino-acid sequence.
  • a permeabilisation or lysis step releases the enzyme variants into the supernatant.
  • the destruction of the m embrane barrier can be forced by the use of mechanical m eans such as ultrasonic, French press, or the use of membrane- digesting enzymes such as lysozyme.
  • the genes encoding the enzyme variants are expressed cell-free by the use of a suitable cell- free expression system .
  • the S30 extract from Escherichia coli cells is used for this purpose as described by Lesly et al. (Methods in Molecular Biology 37 ( 1 995) 265-278) .
  • the ensem ble of gene variants generated and expressed by any of the above methods are analyzed with respect to their affinity, substrate specificity or activity by appropriate assay and screening methods as described in detail for exam ple in patent application PCT/ EP03/ 04864.
  • Genes from catalytically active variants having reduced specificity in com parison to the original enzym e are analyzed by sequencing. Sites at which m utations and/or insertions and/or deletions occurred are preferred insertion sites at which SDRs can be inserted site-specifically.
  • the one or more fully or partially random peptide sequences are inserted at random sites in the protein scaffold.
  • This modification is usually done on the polynucleotide level, i.e. by inserting nucleotide sequences into the gene that encodes the protein scaffold.
  • Several m ethods are available that enable the random insertion of nucleotide sequences.
  • Systems that can be used for random insertion are for exam ple ligation based systems ( Murakam i et al. Nature Biotechnology 20 (2002) 76-81 ) , systems based on DNA polymerisation and transposon based systems (e.g.
  • the transposon-based methods em ploy a transposase- mediated insertion of a selectable marker gene that contains at its term ini recognition sequences for the transposase as well as two sites for a rare cutting restriction endonuclease. Using the latter endonuclease one usually releases the selection marker and after religation obtains an insertion . I nstead of perform ing the religation one can alternatively insert a fragment that has term inal recognition sequences for one or two outside cutting restriction endonuclease as well as a selectable marker. After ligation, one releases this fragment using the one or two outside cutting endonucleases. After creating blunt ends by standard methods one inserts blunt ended random fragments at random positions into the gene.
  • methods for homologous in-vitro recombination are used to combine the m utations introduced by the above mentioned methods to generate enzyme populations.
  • Exam ples of methods that can be applied are the Recom bination Chain Reaction ( RCR) according to patent application WO 0134835, the DNA-Shuffling method according to the patent application WO 9522625, the Staggered Extension method according to patent WO 9842728, or the Random Prim ing recombination according to patent application WO9842728.
  • RCR Recom bination Chain Reaction
  • m ethods for non- homologous recom bination such as the Itchy method can be applied (Ostermeier, M. et al. Nature Biotechnology 1 7 ( 1 999) 1205- 1209) .
  • a library of different genes encoding enzyme variants Upon random insertion of a nucleotide sequence into the protein scaffold one obtains a library of different genes encoding enzyme variants.
  • the polynucleotide library is subsequently transferred to an appropriate expression vector.
  • a library of enzymes containing random ly inserted stretches of am ino acids is obtained.
  • one or more fully or partially random peptide sequences are inserted into the protein scaffold.
  • the actual number of such inserted SDRs is determ ined by the intended quantitative specificity following the relation : the higher the intended specificity is, the more SDRs are inserted.
  • two SDRs enable already the generation of significantly specific enzymes.
  • up to six and more SDRs can be inserted into a protein scaffold.
  • a sim ilar relation is valid for the length of the SDRs: the hig her the intended specificity is, the longer are the SDRs that are to be inserted.
  • SDRs can be as short as one to four am ino acid residues. They can, however, also be as long as 50 am ino acid residues. Significant specificity can already be generated by the use of SDRs of a length of four to six am ino acid residues.
  • the peptid sequences that are inserted can be fully or partially random .
  • fully random m e ans that a set of sequences are inserted in parallel that includes sequences that differ from each other in each and every position.
  • Partially random means that a set of sequences are inserted in parallel that includes sequences that differ from each other in at least one position. This difference can be either pair-wise or with respect to a single sequence.
  • partial random could be a set (i) that includes AGGG, GVGG, GGLG, GGGI , or (ii) that includes AGGG, VGGG, LGGG and I GGG.
  • random sequences also com prises sequences that differ from each other in length.
  • Random ization of the peptide sequences is achieved by random ization of the nucleotide sequences that are inserted into the gene at the respective sites.
  • random ization can be achieved by em ploying m ixtures of nucleobases as monomers during chem ical synthesis of the oligonucleotides.
  • a particularly preferred m ixture of monomers for a fully random codon that in addition m inim izes the probability of stop codons is NN(GTC) .
  • random oligonucleotides can be obtained by fragm entation of DNA into short fragments that are inserted into the gene at the respective sites.
  • the source of the DNA to be fragmented may be a synthetic oligonucleotide but alternatively may originate from cloned genes, cDNAs, or genom ic DNA.
  • the DNA is a gene encoding an enzyme.
  • the fragmentation can, for exam ple, be achieved by random endonucleolytic digestion of DNA.
  • an unspecific endonuclease such as DNAse I (e.g. from bovine pancreas) is em ployed for the endonucleolytic digestion.
  • I f steps (a) - (c) of the inventive method are repeated cyclically, there are different alternatives for obtaining random peptide sequences that are inserted in consecutive rounds.
  • SDRs that were identified in one round as leading to increased specificity of enzyme are used as templates for the random peptide sequences that are inserted in the following round.
  • the sequences selected in one round are analysed and random ized oligonucleotides are generated based on these sequences. This can, for exam ple, be achieved by using in addition to the original nucleotide with a certain percentage m ixtures of the other three nucleotides monomers at each position in the oligonucleotide synthesis. If, for exam ple, in a first round an SDRs is identified that has the am ino acid sequence ARLT, e.g.
  • a random peptide sequence inserted in this SDR site could be encoded by an oligonucleotide with 70% G, 10% A, 10% T and 10% C at the first position, 70% C, 10% G, 1 0% T and 1 0% A at the second position, etc. This leads at each position approximately in 1 of 3 cases to the tem plate am ino acid and in 2 of 3 cases to another am ino acid.
  • sequences selected in one round are analyzed and a consensus library is generated based on these sequences.
  • This can, for exam ple, be achieved by using defined m ixtures of nucleotides at each position in the oligonucleotide synthesis in a way that leads to m ixtures of the am ino acid residues that were identified at each position of the SDR selected in the previous round.
  • a consensus library inserted in this SDR site in the following round could be encoded by an oligonucleotide with the sequence G(CVT)G C(G/ C) C (G/T)(G/T)G (A/T)CC. This would correspond to the random peptide sequence (A/V)( R/ P) ( L/G/V/W) (T/S) , thereby allowing all combinations of the am ino acid residues identified in the first round, and, due to the degeneracy of the genetic code, allowing in addition to a lower degree alternative am ino acid residues at some positions.
  • sequences selected in one round are, without previous analysis, recombined using methods for the in vitro recombination of polynucleotides, such as the m ethods described in WO 01 /34835 (the following also provides details of the eighth and ninth aspect of the invention) .
  • the vector After insertion of the partially or fully random sequences into the gene encoding the scaffold protein, and eventually ligation of the resulting gene into a suitable expression vector using standard molecular cloning techniques (Sambrook, J. F; Fritsch, E. F. ; Maniatis,T. ; Cold Spring Harbor Laboratory Press, Second Edition, 1989, New York) , the vector is introduced in a suitable expression host cell which expresses the corresponding enzym e variant.
  • Particularly suitable expression hosts are bacterial expression hosts such as Escherichia coli or Bacillus subtilis, or yeast expression hosts such as Saccharomyces cerevisae or Pichia pastoris, or mam malian expression hosts such as Chinese Hamster Ovary (CHO) or Baby Hamster Kidney ( BHK) cell lines, or viral expression systems such as bacteriophages like M13 T7 phage or Lambda, or viruses such as the Baculovirus expression system .
  • systems for in vitro protein expression can be used.
  • the DNA is ligated into an expression vector behind a suitable signal sequence that leads to secretion of the enzyme variants into the extracellular space, thereby allowing direct detection of enzyme activity in the cell supernatant.
  • Particularly suitable signal sequences for Escherichia coli are om pA, pelB, HIyA, for Bacillus subtilis AprE, NprB, Mpr, AmyA, AmyE, Blac, SacB, and for S. cerevisiae BaM , Suc2, Mat ⁇ , I nui A, Ggplp.
  • the enzyme variants are expressed intracellular ⁇ and the substrates are expressed also intracellular ⁇ . According to protease variants this is done essentially as described in patent application WO 0212543, using a fusion peptide substrate com prising two auto - fluorescent proteins linked by the substrate am ino-acid sequence.
  • a permeabilisation or lysis step releases the enzyme variants into the supernatant.
  • the destruction of the membrane barrier can be forced by the use of mechanical means such as ultrasonic, French press, or the use of m embrane-digesting enzym es such as lysozyme.
  • the genes encoding the enzyme variants are expressed cell-free by the use of a suitable cell-free expression system .
  • the S30 extract from Escherichia coli cells is used for this purpose as described by Lesly et al. ( Methods in Molecular Biology 37 ( 1995) 265-278) .
  • these cells are screened for the expression of enzymes with specificity for the intended target substrate.
  • screening is typically done by separating the cells from each other, in order to enable the correlation of genotype and phenotype, and assaying the activity of each cell clone after a growth and expression period.
  • separation can for exam ple be done by distribution of the cells into the com partments of sam ple carriers, e.g. as described in WO 01 /24933.
  • the cells are separated by streaking on agar plates, by enclosing in a polymer such as agarose, by filling into capillaries, or by sim ilar m ethods.
  • enzymes that recognize and convert the target sequence preferably are identified by screening for enzymes with a high affinity for the target substrate sequence. High affinity corresponds to a low K/, which is selected by screening at target substrate concentrations substantially below the K M of the first enzyme.
  • the substrates that are used are linked to one or more fluorophores that enable the detection of the modification of the substrate at concentrations below 10 ⁇ M, preferably below 1 ⁇ M, more preferably below 1 00 nM, and m ost preferably below 10 nM.
  • enzymes that recognize and convert the target substrate preferably are identified by em ploying two or m ore substrates in the assay and screening for activity on these two or more substrates in com parison.
  • the two or more substrates em ployed are linked to different marker molecules, thereby enabling the detection of the modification of the two or more substrates consecutively or in parallel.
  • proteases particularly preferably two peptide substrates are em ployed, one peptide substrate having an arbitrarily chosen or even partially or fully random amino-acid sequence thereby enabling to monitor the activity on an arbitrary substrate, and the other peptide substrate having an am ino-acid sequence identical to or resembling the intended target substrate sequence thereby enabling to monitor the activity on the target substrate.
  • these two peptide substrates are linked to fluorescent marker molecules, and the fluorescent properties of the two peptide substrates are sufficiently different in order to distinguish both activities when m easured consecutively or in parallel.
  • a fusion protein com prising a first autofluorescent protein, a peptide, and a second autofluorescent protein according to patent application WO 0212543 can be used for this purpose.
  • fluorophores such as rhodam ines are linked chem ically to the peptide substrates.
  • enzymes that recognize and convert the target substrate preferably are identified by em ploying one or more substrates resembling the target substrate together with com peting substrates in high excess. Screening with respect to activity on the substrates resembling the target substrate is then done in the presence of the com peting substrates. Enzymes having a specificity which corresponds qualitatively to the target specificity, but having only a low quantitative specificity are identified as negative sam ples in such a screen. Whereas enzymes having a specificity which corresponds qualitatively and quantitatively to the target specificity are identified positively.
  • the one or more substrates resem bling the target substrate are linked to marker molecules, thereby enabling the detection of their modifications, whereas the com peting substrates do not carry marker m olecules.
  • the com peting substrates have arbitrarily chosen or random am ino-acid sequences, thereby acting as com petitive inhibitors for the hydrolysis of the marker-carrying substrates.
  • protein hydrolysates such as Trypton can serve as competing substrates for engineered proteolytic enzymes according to the invention.
  • enzymes that recognize and convert the target substrate preferably are identified and selected by an am plification-coupled or growth- coupled selection step. Furthermore, the activity can be measured intracellularily and the selection can be done by a cell sorter, such as a fluorescence- activated cell sorter.
  • enzymes that recognize and convert the target substrate are identified by first selecting enzymes that preferentially bind to the target substrate, and secondly selecting out of this subgroup of enzyme variants those enzymes that convert the target substrate.
  • Selection for enzymes that preferentially bind the target substrate can be either done by selection of binders to the target substrate or by counter-selection of enzym es that bind to other substrates.
  • Methods for the selection of binders or for the counter-selection of non- binders is known in the art. Such methods typically require phenotype-genotype coupling which can be solved by using surface display expression methods. Such methods include, for exam ple, phage or viral display, cell surface display and in vitro display.
  • Phage or viral display typically involves fusion of the protein of interest to a viral/phage protein.
  • Cell surface display i.e. either bacterial or eukaryotic cell display, typically involves fusion of the protein of interest to a peptide or protein that is located at the cell surface.
  • the protein is typically m ade in vitro and linked directly or indirectly to the m RNA encoding the protein ( DE 1 9646372) .
  • the invention also provides for a com position or pharm aceutical com position com prising one or more engineered enzymes according to the first aspect of the invention as defined herein before.
  • the com position may optionally com prise an acceptable carrier, excipient and/or auxiliary agent.
  • Pharmaceutical com positions according to the invention may optionally com prise a pharmaceutically acceptable carrier.
  • Pharmaceutical form ulations are well known and pharmaceutical com positions may be routinely form ulated by one having ordinary skill in the art.
  • the com position can be form ulated as a solution, suspension, em ulsion, or lyophilized powderin association with a pharm aceutically acceptable vehicle. Exam ples of such vehicles are water, saline, Ringer ' s solution, dextrose solution, and human serum album in. Liposomes and nonaaqueous vehicles such as fixed oils may also be used.
  • the vehicle or lyophilized powder may contain additives that m aintain isotonicity (e.g. sodium chloride, mannitol) and chem ical stability (e.g. buffers and preservatives) .
  • the com position is sterilized by com m only used techniques.
  • the pharmaceutical com position of the present invention may be administrated by any means that enables the active agent to reach the agent ' s site of action in the body of a mam mal.
  • Pharm aceutical com positions may be adm inistered parentally, i.e. intravenous (i.v.) , subcutaneous (s.c) , intram uscular.
  • Dosage varies depending upon known factors such as the pharmacodynamic characteristics of the particular agent, and its m ode and route of adm inistration ; age, health, and weight of the recipient; nature and extent of sym ptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
  • Non-pharmaceutical compositions as defined herein are research com position, nutritional com position, cleaning com position, desinfection com position, cosmetic com position or com position for personal care.
  • DNA sequences coding for the engineered enzyme as defined herein before and vectors containing said DNA sequences are also provided.
  • transformed host cells (prokaryotic or eukaryotic) or transgenic organisms containing such DNA sequences and/or vectors, as well as a method ut ilizing such host cells or transgenic animals for producing the engineered enzyme of the first aspect of the invention are also contem plated.
  • Figure 1 Three-dimensional structure of human trypsin I with the active site residues shown in "ball-and-stick” representation and with the marked regions indicating potential SDR insertion sites.
  • Figure 2 Alignment of the primary am ino acid sequences of the human proteases trypsin I , alpha-throm bin and enteropeptidase all of which belong to the structural class S1 of the serine protease fam ily. Trypsin represents an unspecific protease of this structural class, while alpha-thrombin and enteropeptidase are proteases with high substrate specificity. Com pared to trypsin several regions of insertions of three or more am ino acids into the prim ary sequence of a-thrombin and enterokinase are seen. The region marked with (- 1 -) and the region marked with (-3-) are preferred SDR insertion sites.
  • Figure 3 Three-dim ensional structure of subtilisin with the active site residues being shown in "ball-and-stick" representation and with the numbered regions indicating potential SDR insertion sites.
  • Figure 4 Alignment of the primary am ino acid sequences of subtilisin E, furin, FC1 and PC5 all of which belong to the structural class S8 of the serine protease fam ily.
  • Subtilisin E represents an unspecific protease of this structural class, while furin, PC1 and PC5 are proteases with high substrate specificity.
  • Com pared to subtilisin several regions of insertions of three or m ore am ino acids into the primary sequence of furin, PC1 and PC5 are seen. The regions marked with (-4-) , (-5-) , (-7- ) , (-9-) and (- 1 1 -) are preferred SDR insertion sites. These regions stretches fulfill two criteria to be selected as candidates for SDRs: firstly, they represent insertions in the specific proteases com pared to the unspecific one and, secondly, they are close to the active site residues.
  • Figure 5 Three-dimensional structure of beta-secretase with the active site residues being shown in "ball-and-stick" representation and with the numbered regions indicating potential SDR insertion sites.
  • Figure 6 Alignment of the primary am ino acid sequences of pepsin, b-secretase and cathepsin D, all of which belong to the structural class A1 of the aspartic protease fam ily.
  • Pepsin represents an unspecific protease of this structural class, while b-secretase and cathepsin D are proteases with high substrate specificity.
  • Com pared to pepsin several regions of insertions of three or more am ino acids into the prim ary sequence of b-secretase and cathepsin D are seen.
  • the regio ns marked with - 1 - to - 1 1 - correspond to possible SDR com bining sites and are also marked in Fig.5.
  • Figure 7 illustrates the three-dimensional structure of caspase 7 with the active site residues being shown in "ball-and-stick" representation and with the numbered regions indicating potential SDR insertion sites.
  • Figure 8 shows the primary am ino acid sequence of caspase 7 as a member of the cysteine protease class C14 fam ily (see also SEQ I D NO: 14) .
  • Figure 9 Schematic representation of method according to the third aspect of the invention.
  • Figure 10 Western blot analysis of trypsin expression. Supernatant of cell cultures expressing variants of trypsin are com pared to negative controls. Lane 1 : molecular weight standard; lane 2: negative control; lane 3: supernatant of variant a; lane 4: negative control; lane 5 : supernatant of variant b. A primary antibody specific to the expressed protein and a secondary antibody for generation of the signal were used.
  • Figure 1 1 Time course of the proteolytic cleavage of a target substrate. Supernatant of cells containing the vector with the gene for human trypsin and that of cells containing the vector without the gene was incubated with the peptide substrate described in the text. Cleavage of the peptide results in a decreased read out value. Proteolytic activity is confirmed for the positive clone.
  • Figure 12 Relative activity of three engineered proteolytic enzymes in com parison with human trypsin I on two different peptide substrates. A time course of the proteo lytic digestion of the two substrates was performed and evaluated. Substrate B was used for screening and substrate A is a closely related sequence. Relative activity of the three variants was normalized to the activity of human trypsin I . Variant 1 and 2 clearly show increased specificity towards the target substrate. Variant 3, on the other hand, serves as a negative control with sim ilar activities as the human trypsin I .
  • Figure 13 Relative specificities of trypsin and variants of engineered proteolytic enzymes with one or two SDRs, respectively.
  • Activity of the proteases was determ ined in the presence and absence of com petitor substrate, i.e. peptone at a concentration of 10mg/m l.
  • Time courses for the proteolytic cleavage were recorded and the time constants k determ ined.
  • the ratios between the time constants with and without com petitor were formed and represent a quantitative measure for the specificity of the protease.
  • the ratios were norm alized to trypsin.
  • the specificity of the variant containing two SDRs is 2.5 fold higher than that of the variant with SDR2 alone.
  • Figure 14 Shows the relative specificities of protease variants in absence and presence of com petitor substrate.
  • the protease variants containig two inserts with different sequences and the non-modified scaffold human trypsin I were expressed in a suitable host.
  • Activity of the protease variants was determ ined as the cleavage rate of a peptide with the desired target sequence of TNF-alpha in the absence and presence of com petitor substrate. Specificity is expressed as the ratio of cleavage rates in the presence and absence of com petitor.
  • Figure 15 The figure shows the reduction of cytotoxicity induced by human TNF- alpha when incubating the human TNF-alpha with concentrated supernatant from cultures expressing the inventive engineered proteolytic enzymes being specific for human TNF-alpha. This indicates the efficacy of the inventive engineered proteolytic enzymes.
  • Figure 16 The figure shows the reduction of cytotoxicity induced by human TNF- alpha when incubating the human TNF-alpha with different concentrations of purified inventive engineered proteolytic enzyme being specific for human TNF- alpha.
  • Figure 1 7 The figure com pares the activity of inventive engineered proteolytic enzymes being specific for human TNF-alpha with the activity of human trypsin I on two protein substrates: (a) human TNF-alpha; (b) m ixture of human serum proteins. This indicates the safety of the inventive engineered proteolytic enzym es.
  • Variant x corresponds to Seq I D No: 75 com prising the SDRs according to Seq I D No. 89 (SDR1 ) and 95 (SDR2) .
  • Variants xi and xii correspond to derivatives thereof com prising the same SDR sequences.
  • Figure 18 Specific hydrolysis of human VEGF by an engineered proteolytic enzyme derived from human trypsin.
  • trypsin I structural class S1
  • mem bers of the same structural class having a higher sequence specificity.
  • Trypsin represents a member with low substrate specificity, as it requires only an arginine or lysine residue at the P 1 position.
  • thrombin, tissue-type plasm inogen activator or enterokinase all have a high specificity towards their substrate sequences, i.e. ( L/ I/V/ F)XPR ⁇ NA, CPGR ⁇ VVGG and DDDK ⁇ , respectively.
  • SDR1 region one in figure 2, after am ino acid 42 according to SEQ I D NO: 1
  • SDR2 region three in figure 2, after am ino acid 123 according to SEQ I D NO: 1
  • SDR1 region one in figure 2, after am ino acid 42 according to SEQ I D NO: 1
  • SDR2 region three in figure 2, after am ino acid 123 according to SEQ I D NO: 1
  • SDR1 region one in figure 2, after am ino acid 42 according to SEQ I D NO: 1
  • SDR2 region three in figure 2, after am ino acid 123 according to SEQ I D NO: 1
  • the gene encoding the unspecific protease human trypsinogen I was cloned into the vector pUC1 8. Cloning was done as follows: the coding sequence of the protein was amplified by PCR using primers that introduced a Kpnl site at the 5' end and a Bam HI site at the 3' end. This PCR fragment was cloned into the appropriate sites of the vector pUC18. Identity was confirmed by sequencing. After sequencing the coding sequence of the mature protein was am plified by PCR using primers that introduced different BgII sites at the 5' end and the 3' end.
  • This PCR fragment was cloned into the appropriate sites of an E. coli - B. subtilis shuttle vector.
  • the vector contains a pMB1 origin for am plification in E. coli, a neomycin resistance marker for selection in E. coli, as well as a P43 promoter for the constitutive expression in B. subtilis.
  • a 87 bp fragment that contains the leader sequence encoding the signal peptide from the sacB gene of B. subtilis was introduced behind the P43 promoter.
  • Different BgII restriction sites serve as insertion sites for heterologous genes to be expressed.
  • subtilis cells containing the vector with the trypsin I gene in com parison to B. subtilis cells containing the vector without the trypsin I gene (negative control) were analyzed by polyacrylam id gel electrophoreses and subsequent western blot using an antibody specific to the target protease. The procedure was performed according to standard methods (Sambrook, J. F; Fritsch, E.F. ; Maniatis,T. ; Cold Spring Harbor Laboratory Press, Second Edition, 1989, New York) .
  • Figure 8 confirms expression of the protein only in the cells harbouring the vector with the gene for trypsin.
  • Error- prone PCR was done using 30 pmol of each primer, 20 nm ol dGTP and dATP, 1 00 nmol dCTP and dTTP, 20 fmol tem plate, and 5 U Taq DNA polymerase in 10 m M Tris HCI pH 7.6, 50 m M KCI, 7 m M MgCI2, 0.5 m M MnCI2, 0.01 % gelatin for 20 cycles of 1 m in at 94 °C, 1 m in at 65 °C and 1 m in at 72 °C.
  • the resulting DNA library was purified using the Qiaquick PCR Purification Kit following the suppliers' instructions.
  • the PCR product was digested with the restriction enzyme Bgl ⁇ and purified.
  • the PCR product was ligated into the E. coli - B. subtilis shuttle vector described above which was digested with BgII and dephosphorylated.
  • the ligation products were transformed into E. coli, amplified in LB, and the plasm ids were purified using the Qiagen Plasm id Purification Kit following the suppliers' instructions. Resulting plasm ids were transformed into B. subtilis cells.
  • variants of the gene were statistically recombined at homologous positions by use of the Recombination Chain Reaction, essentially as described in WO 0134835.
  • PCR products of the genes encoding the protease variants were purified using the QIAquick PCR Purification Kit following the suppliers' instructions, checked for correct size by agarose gel electrophoresis and m ixed together in equimolar amounts.
  • the partly digested PCR products were refilled with 0.6 U Ru polymerase per ⁇ g DNA by incubating for 15 min at 72 °C in 0.17 mM dNTPs and Ru polymerase buffer according to the suppliers' instructions. After performing a single PCR cycle, the resulting DNA was purified using the QIAquick PCR Purification Kit following the suppliers' instructions, digested with BgII and ligated into the linearized vector. The ligation products were transformed into E. coli, amplified in LB containing am picillin as marker, and the plasmids were purified using the Qiagen Plasmid Purification Kit following the suppliers' instructions. Resulting plasmids were transformed into B. subtilis cells.
  • Example IV Insertion of SDRs into the protein scaffold of human trypsin I and generation of an engineered proteolytic enzyme with specificity for a peptide substrate having the sequence KKWLGRVPGGPV.
  • Reverse primer restr2 (SEQ ID NO:57):
  • Reverse primer restr4 (SEQ ID NO:61):
  • pUC-forward and pUC-reverse are as follows: pUC-forward (SEQ ID NO: 62): 5 ' - GG GGTACCCCACCACCATG AATCCACTCCT- 3 ' pUC- reverse (SEQ I D NO: 63) : 5 ' - CGGG ATCCGGTATAG AG ACTG AAG AG ATAC - 3 '
  • the restriction sites generated thereby were subsequently used to insert defined or random oligonucleotides into the SDR1 and SDR2 insertion sites by standard restriction and ligation methods.
  • oligonucleotide pair according to the following general sequences was used ([P] indicating 5'-phosphorylation, N and X indicating any nucleotide or amino acid residue, respectively): oligox-SDR1f (SEQ ID NO:64):
  • the codon NNB, or VNN in the reverse strand allows all 20 am ino acids to made, but reduces the probability of encoding a stop codon from 0.047 to 0.021 .
  • these SDRs were used as tem plates for further random ization. Thereby, random peptide sequences were inserted that were partially random ized at each position and partially identical at each position to the original sequence.
  • Protease variants were screened on substrate B at com plexities of 1 0 6 variants by confocal fluorescence spectroscopy.
  • the substrate was a peptide biotinylated at the N-term inus and fluorescently labeled at the Gterm inus.
  • streptavidin is added and the sam ples are analysed by confocal fluorimetry.
  • the low concentration of the peptide (2OnM) leads to a preferential cleavage by proteases with a high k cat / K M value, i.e. proteases with high specificity towards the target sequence.
  • Variants selected in the screening procedure were further evaluated for their specificity towards substrate B and closely related substrate A by measuring time courses of the proteolytic digestion and determ ining the rate constants which are proportional to the IW Ky values.
  • the specific activity of variants 1 and 2 is shifted (SEQ I D NOs: 2 and 3, respectively) towards substrate B.
  • Variant 3 (SEQ I D NO: 4) , on the other hand, serves as a negative control with sim ilar activities as the hum an trypsin I . Sequencing of the genes of the three variants revealed the following am ino acid sequences in the SDRs.
  • Table 2 Sequences of the two SDRs in three different variants selected for specific hydrolysis of substrate B (SEQ I D NOs: 78-83) .
  • the ratio of proteolytic activity with and without substrate is a quantitative measure for the specificity of the proteases.
  • Figure 9 shows the relative activities with and without com peting substrate. Human trypsin I that was used as the scaffold protein and two variants, one containing only SDR2, and one containing both SDRs, were com pared. The specificity of the variant with both SDRs is by a factor of 2.5 higher than that of the variant with SDR2 only, confirm ing that there is a direct relation between the number of SDRs and the quantitative specificity of resulting engineered proteolytic enzymes.
  • Exam ple V Generation of an engineered proteolytic enzyme that specifically inactivates human TNF-alpha Human trypsin alpha I or a derivative com prising one or more of the following am ino acid substitutions E56G; R78W; Y131 F; A146T; C183R was used as protein scaffold for the generation of an engineered proteolytic enzyme with high specificity towards human TNF-alpha.
  • the identification of SDR sites in human trypsin I or derivatives thereof was done as described above. Two insertion sites within the scaffold were choosen for SDRs.
  • the protease variants containing two inserts with different sequences and also the human trypsin I itself with no inserts were expressed in a Bacillus subtilis cells.
  • the variant protease cells were separated to single cell clones and the protease expressing variants were screened for proteolytic activity on peptides with the desired target sequence of TNF-alpha.
  • the activity of the protease variants was determ ined as the cleavage rate of a peptide with the desired target sequence of TNF-alpha in the absence and presence of com petitor substrate.
  • the specificity is expressed as the ratio of cleavage rates in the presence and absence of com petitor ( Fig. 14) .
  • Table 3 Relative specificity of variants of engineered proteolytic enzym es with different SDR sequences in absence and presence of com petitor substrate (SEQ I D NOs: 84-95) .
  • TNF-alpha The antagonistic effect of three inventive protease variants on human TNF-alpha is shown in Figure 15.
  • the induction of apoptosis is almost com pletely elim inated indicating the anti- inflam matory efficacy of the inventive proteases to initiate TNF-alpha break down.
  • TNF-alpha has been incubated with concentrated supernatant from cultures expressing the variants i to iii for 2 hours.
  • the resulting TNF-alpha has been incubated with non-m odified cells for 4 hours.
  • the effect of the remaining TNF-alpha activity was determ ined as the extent of apoptosis induction by detection of activated caspase-3 as marker for apoptotic cells.
  • variant x corresponds to Seq I D No: 75 comprising the same SDRs as variant f, i.e. SDRs according to Seq I D No. 89 (SDR1 ) and 95 (SDR2) .
  • variant xi and xii correspond to derivatives thereof comprising the same SDR sequences. Remaining intact protein was was determ ined as a function of time.
  • Human trypsin I was used as protein scaffold for the generation of an engineered proteolytic enzym e with high specificity towards hum an VEGF.
  • the identification of SDR sites in human trypsin I was done as described above. Two insertion sites within the scaffold were choosen for SDRs.
  • the protease variants containing two inserts with different sequences were expressed in Bacillus subtilis cells. The variant protease cells were separated to single cell clones and the protease expressing variants were screened as described above. The activity of the protease variants was determ ined as the rate of VEGF cleavage.

Abstract

La présente invention concerne une méthode pour traiter une maladie. Cette méthode consiste à appliquer un médicament comprenant une protéase qui présente une spécificité définie, capable d'hydrolyser des liaisons peptidiques spécifiques à l'intérieur d'un substrat cible lié à ladite maladie. Les protéases présentant une telle spécificité définie peuvent également être utilisées à des fins thérapeutiques ou diagnostiques liées.
EP05823713A 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci Withdrawn EP1827486A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05823713A EP1827486A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106903 2004-12-22
PCT/EP2005/057061 WO2006067198A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci
EP05823713A EP1827486A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Publications (1)

Publication Number Publication Date
EP1827486A2 true EP1827486A2 (fr) 2007-09-05

Family

ID=36602119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05823713A Withdrawn EP1827486A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Country Status (2)

Country Link
EP (1) EP1827486A2 (fr)
WO (1) WO2006067198A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
ES2640284T3 (es) 2004-04-12 2017-11-02 Catalyst Biosciences, Inc. Polipéptidos MT-SP1 mutantes
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
US9012186B2 (en) 2009-04-27 2015-04-21 The Board Of Trustees Of The University Of Illinois Hemicellulose-degrading enzymes
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
US9982287B2 (en) * 2013-12-17 2018-05-29 Novo Nordisk A/S Enterokinase cleavable polypeptides
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
EP1361284A1 (fr) * 2002-05-10 2003-11-12 Direvo Biotech AG Procédé de préparation des protéases spécifique pour une séquence par evolution dirigée
WO2004067737A2 (fr) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
ATE526399T1 (de) * 2003-06-18 2011-10-15 Bayer Pharma AG Neue biologische einheiten und deren verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006067198A3 *

Also Published As

Publication number Publication date
WO2006067198A2 (fr) 2006-06-29
WO2006067198A3 (fr) 2007-01-04

Similar Documents

Publication Publication Date Title
US20050175581A1 (en) Biological entities and the pharmaceutical and diagnostic use thereof
EP1827486A2 (fr) Nouvelles entites biologiques et utilisation ciblee de celles-ci
EP1633865B1 (fr) Nouvelles entités biologiques et leur utilisation
EP2402437B1 (fr) Procédés de criblage de la protéase et protéases ainsi identifiées
Rockwell et al. The kindest cuts of all: crystal structures of Kex2 and furin reveal secrets of precursor processing
Ballinger et al. Furilisin: A Variant of Subtilisin BPN ‘Engineered for Cleaving Tribasic Substrates
Guerrero et al. Intracellular FRET-based screen for redesigning the specificity of secreted proteases
EP1883696A1 (fr) Serine proteases dont la sensibilite par rapport a des substances modulant l'activite a ete modifiee
CA2475277A1 (fr) Procede pour produire des proteines de recombinaison dans des micro-organismes
CN101842481A (zh) 对柠檬酸盐稳定的中性金属蛋白酶的用途和生产
CA2791144C (fr) Procedes de criblage de proteases et proteases identifiees par lesdits procedes
Pogson et al. Engineering next generation proteases
Milla et al. The TACE zymogen: re-examining the role of the cysteine switch
Rozan et al. Plasticity of extended subsites facilitates divergent substrate recognition by Kex2 and furin
Nagayama et al. Mutated intramolecular chaperones generate high-activity isomers of mature enzymes
Falconer The activation and disarming of Protease-activated receptor 2
JPH07501946A (ja) フィブリン特異性が改善されたｔ‐ＰＡ置換変異体
JP2007295925A (ja) ニューロライシンの発現およびその利用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070619

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIREVO BIOTECH AG

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAUPTS, ULRICH,C/O DIREVO BIOTECH AG

Inventor name: SCHEIDIG, ANDREAS,C/O DIREVO BIOTECH AG

Inventor name: KETTLING, ULRICH,C/O DIREVO BIOTECH AG

Inventor name: COCO, WAYNE MICHAEL,C/O DIREVO BIOTECH AG

Inventor name: KOLTERMANN, ANDRE,C/O DIREVO BIOTECH AG

Inventor name: VOTSMEIER, CHRISTIANC/O DIREVOR BIOTECH AG

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080621